WHO Drug Information, Vol. 26, No. 1, 2012                                                Recommended INN: List 67



International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names:
List 67
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are
selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended
International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or
pharmacy.
Lists of Proposed (1–105) and Recommended (1–66) International Nonproprietary Names can be found in Cumulative List
No. 14, 2011 (available in CD-ROM only).



Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES:
Liste 67
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond.
Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)]
les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes
internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune
recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–105) et recommandées (1–66) dans
la Liste récapitulative No. 14, 2011 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS:
Lista 67
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4
(EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han
sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en
las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la
sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–105) y Recomendadas (1–66) se encuentran
reunidas en Cumulative List No. 14, 2011 (disponible sólo en CD-ROM).


                                                                                                                  45
Recommended INN: List 67                                             WHO Drug Information, Vol. 26, No. 1, 2012




 Latin, English, French, Spanish:
 Recommended INN                    Chemical name or description; Molecular formula; Graphic formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule développée

 DCI Recomendada                    Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada




 abexinostatum
 abexinostat                               3-[(dimethylamino)methyl]-N-{2-[4-
                                           (hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide

 abexinostat                               3-[(diméthylamino)méthyl]-N-{2-[4-
                                           (hydroxycarbamoyl)phénoxy]éthyl}-1-benzofurane-2-carboxamide

 abexinostat                               3-[(dimetilamino)metil]-N-{2-[4-(hidroxicarbamoil)fenoxi]etil}-
                                           1-benzofuran-2-carboxamida

                                           C21H23N3O5

                                                                                   O
                                                                                           OH
                                                        O                              N
                                                                H                      H
                                                                N
                                                                       O
                                            H3C
                                                  N         O

                                             H3C

 amilomotidum #
 amilomotide                               virus like particle of bacteriophage Q-beta coat protein that is
                                           coupled to multiple copies of human beta-amyloid1-6 peptide
                                           fragment;
                                           reaction products of bacteriophage Q-beta coat protein with human
                                           beta-amyloid protein-(1-6)-peptidylglycylglycyl-L-cysteine and
                                           3-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)-N-{6-[(2,5-dioxopyrrolidin-
                                           1-yl)oxy]-6-oxohexyl}propanamide

 amilomotide                               pseudo-particule virale de la capside du phage Q-bêta couplée à
                                           plusieurs copies du fragment 1-6 de la protéine bêta-amyloïde
                                           humaine;
                                           produit obtenu par réaction de la protéine de capside du phage
                                           Q-bêta avec la protéine bêta-amyloïde humaine-
                                           (1-6)peptidylglycylglycyl-L-cystéine et le 3-(2,5-dioxo-2,5-dihydro-
                                           1H-pyrrole-1-yl)-N-{6-[(2,5-dioxopyrrolidin-1-yl)oxy]-
                                           6-oxohexyl}propanamide

 amilomotida                               pseudo-particula viral de cápsida del fago Q-beta acoplada a
                                           múltiples copias del fragmento 1-6 de la proteína beta-amiloide
                                           humana;
                                           producto obtenido por reacción de la proteína de cápsida del fago
                                           Q-beta con la proteína beta-amiloide humana-
                                           (1-6)peptidilglicilglicil-L-cisteína y el 3-(2,5-dioxo-2,5-dihidro-
                                           1H-pirrol-1-il)-N-{6-[(2,5-dioxopirrolidin-1-il)oxi]-
                                           6-oxohexil}propanamida



46
WHO Drug Information, Vol. 26, No. 1, 2012                                                                Recommended INN: List 67




                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             AKLETVTLGN IGKDGKQTLV LNPRGVNPTN GVASLSQAGA VPALEKRVTV 50
                                             SVSQPSRNRK NYKVQVKIQN PTACTANGSC DPSVTRQAYA DVTFSFTQYS 100
                                             TDEERAFVRT ELAALLASPL LIDAIDQLNP AY                    132

                                             Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro
                                             74-80

                                             Modified residues / Résidus modifiés / Residuos modificados
                                                             H CH3                   K                                          H
                                                A
                                                1                           2-13-16-46-60-63-67
                                                      R    N      CO2H                                                  H2N      CO2H
                                                                                                          R     NH
                                                           H
                                                                                  O                   O

                                                                                          N                N                     C
                                                                                                           H
                                                                                                                                 O
                                                                                              O
                                              R = H       or / ou / ó                                          or / ou / ó
                                                                                                      O
                                                                                  O
                                                                                          N                N                     C
                                                                                                           H
                                                                                      *                                          O
                                                                                              O
                                                                                  H       S       H
                                                                                                                  and epimer at C*
                                                                                                                  et l'épimère en C*
                                              H Asp Ala Glu Phe Arg His Gly Gly N                 CO2H            y el epímero al C*
                                                                                H




 anivamersenum
 anivamersen                                 2'-O-methylcytidylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-
                                             methylcytidylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-
                                             methylguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-
                                             methyladenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-
                                             methyladenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-
                                             methyluridylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-
                                             methylcytidylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-
                                             methylcytidine

 anivamersen                                 2'-O-méthylcytidylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-
                                             méthylcytidylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-
                                             méthylguanylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-
                                             méthyladénylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-
                                             méthyladénylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-
                                             méthyluridylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O-
                                             méthylcytidylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-O-
                                             méthylcytidine

 anivamersén                                 2'-O-metilcitidilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metilcitidilil-
                                             (3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-
                                             metiluridilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-O-metiluridilil-(3'→5')-
                                             2'-O-metiladenilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metiluridilil-
                                             (3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-
                                             metiladenilil-(3'→5')-2'-O-metilctidina

                                             C157H208N56O103P14

                                             (3'-5')-mC-mG-mC-mG-mG-mU-mA-mU-mA-mG-mU-mC-mC-mA-mC




                                                                                                                                        47
Recommended INN: List 67                                     WHO Drug Information, Vol. 26, No. 1, 2012


 asunaprevirum
 asunaprevir               tert-butyl {(2S)-1-[(2S,4R)-4-({7-chloro-4-methoxyisoquinolin-
                           1-yl}oxy)-2-({(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-
                           2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-
                           1-oxobutan-2-yl}carbamate

 asunaprévir               (2S)-1-[(2S,4R)-4-({7-chloro-4-méthoxyisoquinolin-1-yl}oxy)-
                           2-({(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-
                           2-éthènylcyclopropyl}carbamoyl)pyrrolidin-1-yl]-3,3-diméthyl-
                           1-oxobutan-2-yl}carbamate de tert-butyle

 asunaprevir               {(2S)-1-[(2S,4R)-4-({7-cloro-4-metoxiisoquinolin-1-il}oxi)-2-({(1R,2S)-
                           1-[(ciclopropanosulfonil)carbamoil]-
                           2-etenilciclopropil}carbamoil)pirrolidin-1-il]-3,3-dimetil-1-oxobutan-
                           2-il}carbamato de terc-butilo

                           C35H46ClN5O9S

                                             O
                                            O S
                                    O         NH
                                                   O
                                                       H                              OCH3
                                                                         N
                           H2C                N                      H
                                              H
                                     H        O        N             O
                             H 3C   CH3 O
                                                           CH3
                            H3C         O     N             CH3
                                              H H                                Cl
                                                       CH3



 atecegatranum metoxilum
 atecegatran metoxil       (2S)-1-{(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-
                           2-hydroxyacetyl}-N-({4-[(Z)-N'-
                           methoxycarbamimidoyl]phenyl}methyl)azetidine-2-carboxamide

 atécégatran métoxil       (2S)-1-{(2R)-2-[3-chloro-5-(difluorométhoxy)phényl]-
                           2-hydroxyacétyl}-N-({4-[(Z)-N'-
                           méthoxycarbamimidoyl]phényl}méthyl)azétidine-2-carboxamide

 atecegatrán metoxilo      (2S)-1-{(2R)-2-[3-cloro-5-(difluorometoxi)fenil]-2-hidroxiacetil}-
                           N-({4-[(Z)-N'-metoxicarbamimidoil]fenil}metil)azetidina-
                           2-carboxamida

                           C22H23ClF2N4O5

                           H3CO
                                    N

                             H2N                                             H OH
                                                       H
                                                       N                 N                     Cl
                                                                 H
                                                             O               O

                                                                                       O       F

                                                                                           F




48
WHO Drug Information, Vol. 26, No. 1, 2012                                                                  Recommended INN: List 67


 avagacestatum
 avagacestat                                 (2R)-2-(4-chloro-N-{[2-fluoro-4-(1,2,4-oxadiazol-
                                             3-yl)phenyl]methyl}benzenesulfonamido)-5,5,5-trifluoropentanamide

 avagacestat                                 (2R)-2-(4-chloro-N-{[2-fluoro-4-(1,2,4-oxadiazol-
                                             3-yl)phényl]méthyl}benzenesulfonamido)-5,5,5-trifluoropentanamide

 avagacestat                                 (2R)-2-(4-cloro-N-{[2-fluoro-4-(1,2,4-oxadiazol-
                                             3-yl)fenil]metil}bencenosulfonamido)-5,5,5-trifluoropentanamida

                                             C20H17ClF4N4O4S

                                                                                                Cl
                                              O N
                                                                        O
                                               N                    O       S
                                                                            N                   CF3
                                                                                    H
                                                           F
                                                                            O       NH2


 besifovirum
 besifovir                                   [({1-[(2-amino-9H-purin-
                                             9-yl)methyl]cyclopropyl}oxy)methyl]phosphonic acid

 bésifovir                                   acide [({1-[(2-amino-9H-purin-
                                             9-yl)méthyl]cyclopropyl}oxy)méthyl]phosphonique

 besifovir                                   ácido [({1-[(2-amino-9H-purin-9-il)metil]ciclopropil}oxi)metil]fosfónico

                                             C10H14N5O4P

                                                                N                   O
                                                   N                                        OH
                                                                                        P
                                                                                            OH
                                             H2N       N        N               O




 bitopertinum
 bitopertin                                  {4-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}[5-
                                             (methanesulfonyl)-2-{[(2S)-1,1,1-trifluoropropan-
                                             2-yl]oxy}phenyl]methanone

 bitopertine                                 {4-[3-fluoro-5-(trifluorométhyl)pyridin-2-yl]pipérazin-1-yl}[5-
                                             (méthanesulfonyl)-2-{[(2S)-1,1,1-trifluoropropan-
                                             2-yl]oxy}phényl]méthanone

 bitopertina                                 {4-[3-fluoro-5-(trifluorometil)piridin-2-il]piperazin-1-il}[5-
                                             (metanosulfonil)-2-{[(2S)-1,1,1-trifluoropropan-
                                             2-il]oxy}fenil]metanona

                                             C21H20F7N3O4S

                                                 O O                 O
                                                  S
                                             H3 C                           N                   F
                                                                                    N
                                                                     O
                                                               H                            N
                                                                            CF3                       CF3
                                                               H3C




                                                                                                                                  49
Recommended INN: List 67                                    WHO Drug Information, Vol. 26, No. 1, 2012




 blosozumabum #
 blosozumab                immunoglobulin G4-kappa, anti-[Homo sapiens SOST (sclerostin)],
                           humanized monoclonal antibody;
                           gamma4 heavy chain (1-444) [humanized VH (Homo sapiens
                           IGHV1-24*01 (85.70%) -(IGHD)-IGHJ4*01 L123>T (113)) [8.8.11] (1-
                           118) -Homo sapiens IGHG4*01 hinge S10>P (226), CH3 K120>del
                           (119-444)], (132-214')-disulfide with kappa light chain (1'-214')
                           [humanized V-KAPPA (Homo sapiens IGKV1-13*02 (84.00%) -
                           IGKJ1*01 Q120>G (100)) [6.3.9] (1'-107') -Homo sapiens IGKC*01
                           (108'-214')]; (224-224":227-227")-bisdisulfide dimer

 blosozumab                immunoglobuline G4-kappa, anti-[Homo sapiens SOST
                           (sclérostine)], anticorps monoclonal humanisé;
                           chaîne lourde gamma4 (1-444) [VH humanisé (Homo sapiens
                           IGHV1-24*01 (85.70%) -(IGHD)-IGHJ4*01 L123>T (113)) [8.8.11] (1-
                           118) -Homo sapiens IGHG4*01 charnière S10>P (226), CH3
                           K120>del (119-444)], (132-214')-disulfure avec la chaîne légère
                           kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-13*02
                           (84.00%) -IGKJ1*01 Q120>G (100)) [6.3.9] (1'-107') -Homo sapiens
                           IGKC*01 (108'-214')]; dimère (224-224":227-227")-bisdisulfure

 blosozumab                inmunoglobulina G4-kappa, anti-[Homo sapiens SOST
                           (esclerostina)], anticuerpo monoclonal humanizado;
                           cadena pesada gamma4 (1-444) [VH humanizada (Homo sapiens
                           IGHV1-24*01 (85.70%) -(IGHD)-IGHJ4*01 L123>T (113)) [8.8.11] (1-
                           118) -Homo sapiens IGHG4*01 bisagra S10>P (226), CH3 K120>del
                           (119-444)], (132-214')-disulfuro con la cadena ligera kappa (1'-214')
                           [V-KAPPA humanizada (Homo sapiens IGKV1-13*02 (84.00%) -
                           IGKJ1*01 Q120>G (100)) [6.3.9] (1'-107') -Homo sapiens IGKC*01
                           (108'-214')]; dímero (224-224":227-227")-bisdisulfuro


                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGASVKV SCKVSGFPIK                  DTFQHWVRQA       PGKGLEWMGW        50
                           SDPEIGDTEY ASKFQGRVTM TEDTSTDTAY                  MELSSLRSED       TAVYYCATGD       100
                           TTYKFDFWGQ GTTVTVSSAS TKGPSVFPLA                  PCSRSTSEST       AALGCLVKDY       150
                           FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSSLGTKTYT       200
                           CNVDHKPSNT KVDKRVESKY GPPCPPCPAP                  EFLGGPSVFL       FPPKPKDTLM       250
                           ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV                  EVHNAKTKPR       EEQFNSTYRV       300
                           VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI                  EKTISKAKGQ       PREPQVYTLP       350
                           PSQEEMTKNQ VSLTCLVKGF YPSDIAVEWE                  SNGQPENNYK       TTPPVLDSDG       400
                           SFFLYSRLTV DKSRWQEGNV FSCSVMHEAL                  HNHYTQKSLS       LSLG             444

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCKASQDVH                  TAVAWYQQKP       GKAPKLLIYW 50
                           ASTRWTGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQQ       YSDYPWTFGG 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        145-201       259-319  365-423
                                     22''-96'' 145''-201'' 259''-319'' 365''-423''
                           Intra-L 23'-88'      134'-194'
                                    23'''-88''' 134'''-194'''
                           Inter-H-L 132-214' 132''-214'''
                           Inter-H-H 224-224'' 227-227''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           295, 295''




50
WHO Drug Information, Vol. 26, No. 1, 2012                                                           Recommended INN: List 67


 brodalumabum #
 brodalumab                                  immunoglobulin G2-kappa, anti-[Homo sapiens IL17RA (interleukin
                                             17 receptor A, CD217)], Homo sapiens monoclonal antibody;
                                             gamma2 heavy chain (1-442) [Homo sapiens VH (IGHV1-18*01
                                             (96.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -Homo sapiens
                                             IGHG2*01 (117-442)], (130-214')-disulfide with kappa light chain
                                             (1'-214') [Homo sapiens V-KAPPA (IGKV1-15*01 (93.70%) -
                                             IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')];
                                             (218-218":219-219":222-222":225-225")-tetrakisdisulfide dimer

 brodalumab                                  immunoglobuline G2-kappa, anti-[Homo sapiens IL17RA (récepteur
                                             A de l'interleukine 17, CD217)], Homo sapiens anticorps monoclonal;
                                             chaîne lourde gamma2 (1-442) [Homo sapiens VH (IGHV1-18*01
                                             (96.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -Homo sapiens
                                             IGHG2*01 (117-442)], (130-214')-disulfure avec la chaîne légère
                                             kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-15*01 (93.70%) -
                                             IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')];
                                             dimère (218-218":219-219":222-222":225-225")-tétrakisdisulfure

 brodalumab                                  inmunoglobulina G2-kappa, anti-[IL17RA (receptor A de la
                                             interleukina 17 de Homo sapiens, CD217)], anticuerpo monoclonal
                                             de Homo sapiens;
                                             cadena pesada gamma2 (1-442) [Homo sapiens VH (IGHV1-18*01
                                             (96.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -Homo sapiens
                                             IGHG2*01 (117-442)], (130-214')-disulfuro con la cadena ligera
                                             kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-15*01 (93.70%) -
                                             IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')];
                                             dímero (218-218":219-219":222-222":225-225")-tetrakisdisulfuro

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLVQSGAE VKKPGASVKV SCKASGYTFT                  RYGISWVRQA       PGQGLEWMGW        50
                                             ISTYSGNTNY AQKLQGRVTM TTDTSTSTAY                  MELRSLRSDD       TAVYYCARRQ       100
                                             LYFDYWGQGT LVTVSSASTK GPSVFPLAPC                  SRSTSESTAA       LGCLVKDYFP       150
                                             EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS                  LSSVVTVPSS       NFGTQTYTCN       200
                                             VDHKPSNTKV DKTVERKCCV ECPPCPAPPV                  AGPSVFLFPP       KPKDTLMISR       250
                                             TPEVTCVVVD VSHEDPEVQF NWYVDGVEVH                  NAKTKPREEQ       FNSTFRVVSV       300
                                             LTVVHQDWLN GKEYKCKVSN KGLPAPIEKT                  ISKTKGQPRE       PQVYTLPPSR       350
                                             EEMTKNQVSL TCLVKGFYPS DIAVEWESNG                  QPENNYKTTP       PMLDSDGSFF       400
                                             LYSKLTVDKS RWQQGNVFSC SVMHEALHNH                  YTQKSLSLSP       GK               442

                                             Light chain / Chaîne légère / Cadena ligera
                                             EIVMTQSPAT LSVSPGERAT LSCRASQSVS                  SNLAWFQQKP       GQAPRPLIYD 50
                                             ASTRATGVPA RFSGSGSGTD FTLTISSLQS                  EDFAVYYCQQ       YDNWPLTFGG 100
                                             GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96        143-199       256-316  362-420
                                                       22''-96'' 143''-199'' 256''-316'' 362''-420''
                                             Intra-L 23'-88'      134'-194'
                                                      23'''-88''' 134'''-194'''
                                             Inter-H-L 130-214' 130''-214'''
                                             Inter-H-H 218-218'' 219-219'' 222-222'' 225-225''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             292, 292''



 cabozantinibum
 cabozantinib                                N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-
                                             N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

 cabozantinib                                N-{4-[(6,7-diméthoxyquinoléin-4-yl)oxy]phényl}-
                                             N'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide

 cabozantinib                                N-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-
                                             N'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida



                                                                                                                                         51
Recommended INN: List 67                                     WHO Drug Information, Vol. 26, No. 1, 2012




                           C28H24FN3O5

                           H3CO                  N


                           H3CO
                                                 O                                                F
                                                                     O       O

                                                                 N               N
                                                                 H               H



 calaspargasum pegolum #
 calaspargase pegol        pegylated Escherichia coli asparaginase;
                           [27-alanine,64-aspartic acid,252-threonine,263-asparagine]-
                           L-asparaginase 2 (EC 3.5.1.1, L-asparagine amidohydrolase II)
                           Escherichia coli (strain K12) tetramer α4, carbamates with α-carboxy-
                           ω-methoxypoly(oxyethylene)

 calaspargase pégol        asparaginase d'Escherichia coli pégylée;
                           carbamates entre le tétramère α4 de [27-alanine,64-acide
                           aspartique,252-thréonine,263-asparagine]-L-asparaginase 2 (EC
                           3.5.1.1, L-asparagine amidohydrolase II) d'Escherichia coli (souche
                           K12) et le α-carboxy-ω-méthoxypoly(oxyéthylène)

 calaspargasa pegol        asparaginasa de Escherichia coli pegilada;
                           carbamatos entre el tetrámero α4 de [27-alanina,64-ácido
                           aspártico,252-treonina,263-asparagina]-L-asparaginasa 2 (EC
                           3.5.1.1, L-asparagina amidohidrolasa II) de Escherichia coli (cepa
                           K12) y el α-carboxi-ω-metoxipoli(oxietileno)

                           C1516H2423N415O492S8 (peptide monomer)

                           Monomer / Monomère / Monómero

                           LPNITILATG       GTIAGGGDSA       TKSNYTAGKV       GVENLVNAVP       QLKDIANVKG      50
                           EQVVNIGSQD       MNDDVWLTLA       KKINTDCDKT       DGFVITHGTD       TMEETAYFLD      100
                           LTVKCDKPVV       MVGAMRPSTS       MSADGPFNLY       NAVVTAADKA       SANRGVLVVM      150
                           NDTVLDGRDV       TKTNTTDVAT       FKSVNYGPLG       YIHNGKIDYQ       RTPARKHTSD      200
                           TPFDVSKLNE       LPKVGIVYNY       ANASDLPAKA       LVDAGYDGIV       SAGVGNGNLY      250
                           KTVFDTLATA       AKNGTAVVRS       SRVPTGATTQ       DAEVDDAKYG       FVASGTLNPQ      300
                           KARVLLQLAL       TQTKDPQQIQ       QIFNQY                                            326
                           approximately 9 residues are pegylated out of 23 (1 L and 22 K)
                           environ 9 résidus sur 23 (1 L et 22 K) sont pegylés
                           aproximadamente están pegilados 9 restos de 23 ( 1L y 22K)

                                                 L                                              K
                                                 1                          22-29-43-49-71-72-79-104-107-139-162-172-
                                                                            186-196-207-213-229-251-262-288-301-314
                                                         CH3
                                                 H3 C                                         O                 H
                                                 O H
                                                                                 O                       H2N      CO2H
                                   O                                      H3C             O       N
                             H3C             O       N    CO2H                                n   H
                                                 n   H
                                                                                              n # 112
                                           n # 112

                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                            77-105 77'-105' 77'''-105''' 77''''-105''''




52
WHO Drug Information, Vol. 26, No. 1, 2012                                             Recommended INN: List 67




 cantuzumabum ravtansinum #
 cantuzumab ravtansine                       immunoglobulin G1-kappa, anti-[Homo sapiens MUC1 sialylated
                                             carbohydrate, tumour-associated (CA242, cancer antigen 242)],
                                             humanized monoclonal antibody conjugated to maytansinoid DM4;
                                             gamma1 heavy chain (1-449) [humanized VH (Homo sapiens
                                             IGHV7-4-1*02 (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T
                                             (114)) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-449)], (222-
                                             219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA
                                             (Homo sapiens IGKV2-28*01 (82.00%) -IGKJ3*01 V124>L (109),
                                             D125>E (110), I126>L (111)) [11.3.9] (1'-112') -Homo sapiens
                                             IGKC*01 (113'-219')]; (228-228":231-231")-bisdisulfide dimer ;
                                             conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM4
                                               2'            2'
                                             [N -deacetyl-N -(4-mercapto-4-methyl-1-oxopentyl)-maytansine] via
                                             the reducible SPDB linker [N-succinimidyl 4-(2-
                                             pyridyldithio)butanoate]
                                             For the ravtansine part, please refer to the document "INN for
                                             pharmaceutical substances: Names for radicals, groups and others"*

 cantuzumab ravtansine                       immunoglobuline G1-kappa, anti-[Homo sapiens glycane sialylé de
                                             MUC1, associé à des tumeurs (CA242, antigène du cancer 242)],
                                             anticorps monoclonal humanisé conjugué au maytansinoïde DM4;
                                             chaîne lourde gamma1 (1-449) [VH humanisé (Homo sapiens
                                             IGHV7-4-1*02 (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T
                                             (114)) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-449)], (222-
                                             219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA
                                             humanisé (Homo sapiens IGKV2-28*01 (82.00%) -IGKJ3*01 V124>L
                                             (109), D125>E (110), I126>L (111)) [11.3.9] (1'-112') -Homo sapiens
                                             IGKC*01 (113'-219')]; dimère (228-228":231-231")-bisdisulfure;
                                                                                                              2'
                                             conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM4 [N -
                                                         2'
                                             déacétyl-N -(4-mercapto-4-méthyl-1-oxopentyl)-maytansine] via le
                                             linker SPDB réductible [4-(2-pyridyldithio)butanoate de N-
                                             succinimidyle]
                                             Pour la partie ravtansine, veuillez vous référer au document "INN for
                                             pharmaceutical substances: Names for radicals, groups and
                                             others"*.

 cantuzumab ravtansina                       inmunoglobulina G1-kappa, anti-[Homo sapiens glicano sialilo de
                                             MUC1, asociado al tumor (CA242, antígeno del cancer 242)]
                                             anticuerpo monoclonal humanizado conjugado con el maitansinoide
                                             DM4;
                                             cadena pesada gamma1 (1-449) [VH humanizada (Homo sapiens
                                             IGHV7-4-1*02 (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T
                                             (114)) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-449)], (222-
                                             219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA
                                             humanizada (Homo sapiens IGKV2-28*01 (82.00%) -IGKJ3*01
                                             V124>L (109), D125>E (110), I126>L (111)) [11.3.9] (1'-112') -Homo
                                             sapiens IGKC*01 (113'-219')]; dímero (228-228":231-231")-
                                             bisdisulfuro; conjugado, en 3-4 grupos lisil por término medio, con el
                                                                     2'            2'
                                             maitansinoide DM4 [N -desacetil-N -(4-mercapto-4-metil-1-
                                             oxopentil)-maitansina] mediante el conector SPDB reducible [N-4-(2-
                                             piridilditio)butanoato de succinimidilo]
                                             Para la fracción ravtansina, se ruega referirse al documento "INN for
                                             pharmaceutical substances: Names for radicals, groups and
                                             others"*.




                                                                                                                  53
Recommended INN: List 67                                         WHO Drug Information, Vol. 26, No. 1, 2012




                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGETVKI SCKASDYTFT                      YYGMNWVKQA   PGQGLKWMGW        50
                           IDTTTGEPTY AQKFQGRIAF SLETSASTAY                      LQIKSLKSED   TATYFCARRG       100
                           PYNWYFDVWG QGTTVTVSSA STKGPSVFPL                      APSSKSTSGG   TAALGCLVKD       150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                      LYSLSSVVTV   PSSSLGTQTY       200
                           ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                      CPAPELLGGP   SVFLFPPKPK       250
                           DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                      VDGVEVHNAK   TKPREEQYNS       300
                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                      PAPIEKTISK   AKGQPREPQV       350
                           YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                      VEWESNGQPE   NNYKTTPPVL       400
                           DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                      HEALHNHYTQ   KSLSLSPGK        449

                           Light chain / Chaîne légère / Cadena ligera
                           DIVMTQSPLS VPVTPGEPVS ISCRSSKSLL                      HSNGNTYLYW   FLQRPGQSPQ 50
                           LLIYRMSNLV SGVPDRFSGS GSGTAFTLRI                      SRVEAEDVGV   YYCLQHLEYP 100
                           FTFGPGTKLE LKRTVAAPSV FIFPPSDEQL                      KSGTASVVCL   LNNFYPREAK 150
                           VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                      SSTLTLSKAD   YEKHKVYACE 200
                           VTHQGLSSPV TKSFNRGEC                                                          219

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        146-202       263-323  369-427
                                    22''-96'' 146''-202'' 263''-323'' 369''-427''
                           Intra-L 23'-93'      139'-199'
                                    23'''-93''' 139'''-199'''
                           Inter-H-L 222-219' 222''-219'''
                           Inter-H-H 228-228'' 231-231''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           299, 299''



 ceftolozanum
 ceftolozane               (6R,7R)-3-[(5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-
                           1H-pyrazol-2-ium-2-yl)methyl]-7-[(2Z)-2-(5-amino-1,2,4-thiadiazol-
                           3-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetamido]-8-oxo-5-thia-
                           1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

 ceftolozane               (6R,7R)-3-[(5-amino-4-{[(2-aminoéthyl)carbamoyl]amino}-1-méthyl-
                           1H-pyrazol-2-ium-2-yl)méthyl]-7-[(2Z)-2-(5-amino-1,2,4-thiadiazol-
                           3-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acétamido]-8-oxo-5-thia-
                           1-azabicyclo[4.2.0]oct-2-ène-2-carboxylate

 ceftolozano               (6R,7R)-3-[(5-amino-4-{[(2-aminoetil)carbamoil]amino}-1-metil-
                           1H-pirazol-2-io-2-il)metil]-7-[(2Z)-2-(5-amino-1,2,4-tiadiazol-3-il)-
                           2-{[(2-carboxipropan-2-il)oxo]imino}acetamido]-8-oxo-5-tia-
                           1-azabiciclo[4.2.0]oct-2-eno-2-carboxilato

                           C23H30N12O8S2

                                          H3 C                                                         NH2
                                                     CO2H
                                      H3C                         CO2                   O
                                                 O   O
                                                                                              NH
                                           N                 N               N
                                                     H                                  NH
                                  N                  N                       N
                                                                  S   H3 C
                             S                           H   H
                                      N          O                                NH2

                           H2 N



 cenderitidum
 cenderitide               natriuretic peptide receptor type B (NPR-B) agonist;
                           human C-type natriuretic peptide-(32-53)-peptide (CNP-22) fusion
                           protein with eastern green mamba (Dendroaspis angusticeps)
                           natriuretic peptide-(24-38)-peptide




54
WHO Drug Information, Vol. 26, No. 1, 2012                                                              Recommended INN: List 67


 cendéritide                                 agoniste du récepteur du peptide natriurétique de type B;
                                             peptide natriurétique de type-C humain-(32-53)-peptide (CNP-22)
                                             protéine de fusion avec le peptide natriurétique de Dendroaspis
                                             angusticeps (mamba vert)-(24-38)-peptide

 cenderitida                                 agonista del receptor del péptido natriurético de tipo B;
                                             péptido natriurético de tipo-C humano-(32-53)-péptido (CNP-22)
                                             proteína de fusión con el péptido natriurético de Dendroaspis
                                             angusticeps (mamba vert)-(24-38)-péptido

                                             C158H263N49O50S3

                                             GLSKGCFGLK          LDRIGSMSGL             GCPSLRDPRP           NAPSTSA 37

                                             Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro
                                             6-22




 cepeginterferonum alfa-2b #
 cepeginterferon alfa-2b                     pegylated human interferon alpha-2b;
                                              2.1
                                             N -{4-[ω-methoxypoly(oxyethylene)]butyl}-human interferon alpha-
                                             2b

 cépeginterféron alfa-2b                     interféron alpha-2b humain pégylé;
                                               2.1
                                             N -{4-[ω-méthoxypoly(oxyéthylène)]butyl}-interféron alpha-2b
                                             humain

 cepeginterferón alfa-2b                     interferón alfa-2b humano pegilado;
                                               2.1
                                             N -{4-[ω-metoxipoli(oxietileno)]butil}-interferón alfa-2b humano

                                             C865H1359N229O256S9 [C2H4O]n

                                             CDLPQTHSLG      SRRTLMLLAQ MRRISLFSCL KDRHDFGFPQ EEFGNQFQKA 50
                                             ETIPVLHEMI      QQIFNLFSTK DSSAAWDETL LDKFYTELYQ QLNDLEACVI 100
                                             QGVGVTETPL      MKEDSILAVR KYFQRITLYL KEKKYSPCAW EVVRAEIMRS 150
                                             FSLSTNLQES      LRSKE                                       165

                                             Disulfide bridges location / Positions des ponts disulfure / Posiciones de los puentes disulfuro
                                             1-98 29-138

                                             Modified residue / Résidu modifié / Residuo modificado
                                                                                                    H
                                                C                        O                          N     CO2H
                                                                   H3C              O
                                                1                                   n
                                                                                               HS        H
                                                                          n # 450




 conberceptum #
 conbercept                                  fusion protein for immune applications (FPIA) comprising Homo
                                             sapiens FLT1 (fms-related tyrosine kinase 1, vascular endothelial
                                             growth factor receptor 1, VEGFR1, vascular permeability factor
                                             receptor, tyrosine-protein kinase FRT) fragment, fused with Homo
                                             sapiens KDR (kinase insert domain receptor, vascular endothelial
                                             growth factor receptor 2, VEGFR2, protein-tyrosine kinase receptor
                                             FLK1, CD309) fragment, fused with Homo sapiens immunoglobulin
                                             G1 Fc fragment;
                                             FLT1, 132-232 precursor fragment (1-101) -KDR, 227-421 precursor
                                             fragment (102-296) -glycyl-prolyl-glycyl (297-299) -gamma1 chain
                                             H-CH2-CH3 fragment (300-526) [Homo sapiens IGHG1*03 hinge
                                             6-15 P13>L (307) (300-309), CH2 (310-419), CH3-CH-S (420-526)];
                                             (305-305':308-308')-bisdisulfide dimer




                                                                                                                                          55
Recommended INN: List 67                                    WHO Drug Information, Vol. 26, No. 1, 2012


 conbercept                protéine de fusion pour applications immunitaires (FPIA) comprenant
                           un fragment d'Homo sapiens FLT1 (tyrosine kinase 1 apparentée au
                           fms, récepteur 1 du facteur de croissance de l'endothélium
                           vasculaire, VEGFR1, récepteur du facteur de perméabilité
                           vasculaire, tyrosine-protéine kinase FRT), fusionné à un fragment
                           d'Homo sapiens KDR (récepteur à domaine kinase, récepteur 2 du
                           facteur de croissance de l'endothélium vasculaire, VEGFR2,
                           récepteur tyrosine-protéine kinase FLK1, CD309), fusionné au
                           fragment Fc de l'Homo sapiens immunoglobuline G1;
                           FLT1, fragment 132-232 du précurseur (1-101) -KDR, fragment
                           227-421 du précurseur (102-296) - glycyl-prolyl-glycyl (297-299) -
                           fragment H-CH2-CH3 de la chaîne gamma1 (300-526) [Homo
                           sapiens IGHG1*03 charnière 6-15 P13>L (307) (300-309), CH2
                           (310-419), CH3-CH-S (420-526)]; dimère (305-305':308-308')-
                           bisdisulfure

 conbercept                proteína de fusión para aplicaciones inmunitarias (FPIA) que
                           comprende un fragmento de FLT1 de Homo sapiens (tirosina kinasa
                           1 relacionada con fms, receptor 1 del factor de crecimiento del
                           endotelio vascular, VEGFR1, receptor del factor de permeabilidad
                           vascular, tirosina-protein kinasa FRT), fusionada a un fragmento de
                           KDR de Homo sapiens (receptor con dominio kinasa, receptor 2 del
                           factor de crecimiento del endotelio vascular, VEGFR2, receptor
                           tirosina-protein kinasa FLK1, CD309), fusionado al fragmento Fc de
                           la inmunoglobulina G1 de Homo sapiens;
                           FLT1, fragmento 132-232 de precursor (1-101) -KDR, fragmento
                           227-421 del precursor (102-296) - glicil-prolil-glicil (297-299) -
                           fragmento H-CH2-CH3 de la cadena gamma1 (300-526) [Homo
                           sapiens IGHG1*03 bisagra 6-15 P13>L (307) (300-309), CH2 (310-
                           419), CH3-CH-S (420-526)]; dímero (305-305':308-308')-bisdisulfuro

                           Fused chain / chaine fusionnée / cadena fusionada
                           GRPFVEMYSE IPEIIHMTEG RELVIPCRVT SPNITVTLKK                        FPLDTLIPDG        50
                           KRIIWDSRKG FIISNATYKE IGLLTCEATV NGHLYKTNYL                        THRQTNTIID       100
                           VVLSPSHGIE LSVGEKLVLN CTARTELNVG IDFNWEYPSS                        KHQHKKLVNR       150
                           DLKTQSGSEM KKFLSTLTID GVTRSDQGLY TCAASSGLMT                        KKNSTFVRVH       200
                           EKPFVAFGSG MESLVEATVG ERVRIPAKYL GYPPPEIKWY                        KNGIPLESNH       250
                           TIKAGHVLTI MEVSERDTGN YTVILTNPIS KEKQSHVVSL                        VVYVPPGPGD       300
                           KTHTCPLCPA PELLGGPSVF LFPPKPKDTL MISRTPEVTC                        VVVDVSHEDP       350
                           EVKFNWYVDG VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ                        DWLNGKEYKC       400
                           KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSRDELTKN                        QVSLTCLVKG       450
                           FYPSDIAVEW ESNGQPENNY KATPPVLDSD GSFFLYSKLT                        VDKSRWQQGN       500
                           VFSCSVMHEA LHNHYTQKSL SLSPGK                                                        526

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-chain 27-76 121-182 340-400 446-504
                                        27'-76' 121'-182' 340'-400' 446'-504'
                           Inter-chains 305-305' 308-308'

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           376, 376'



 crenezumabum #
 crenezumab                immunoglobulin G4-kappa, anti-[Homo sapiens amyloid beta (Abeta)
                           peptides Aβ42 and Aβ40)], humanized monoclonal antibody;
                           gamma4 heavy chain (1-438) [humanized VH (Homo sapiens
                           IGHV3-23*04 (89.70%) -(IGHD)-IGHJ4*01 L123>T (107) [8.8.5]
                           (1-112) -Homo sapiens IGHG4*01 hinge S10>P (220) (113-438)],
                           (126-219')-disulfide with kappa light chain (1'-219') [humanized
                           V-KAPPA (Homo sapiens IGKV2D-29*02 (86.00%) -IGKJ1*01)
                           [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; (218-
                           218":221-221")-bisdisulfide dimer




56
WHO Drug Information, Vol. 26, No. 1, 2012                                                           Recommended INN: List 67


 crénezumab                                  immunoglobuline G4-kappa, anti-[Homo sapiens peptides bêta-
                                             amyloïdes (Abêta) Aβ42 et Aβ40)], anticorps monoclonal humanisé;
                                             chaîne lourde gamma4 (1-438) [VH humanisé (Homo sapiens
                                             IGHV3-23*04 (89.70%) -(IGHD)-IGHJ4*01 L123>T (107) [8.8.5]
                                             (1-112) -Homo sapiens IGHG4*01 charnière S10>P (220) (113-
                                             438)], (126-219')-disulfure avec la chaîne légère kappa (1'-219')
                                             [V-KAPPA humanisé (Homo sapiens IGKV2D-29*02 (86.00%) -
                                             IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')];
                                             dimère (218-218":221-221")-bisdisulfure

 crenezumab                                  inmunoglobulina G4-kappa, anti-[péptidos beta-amiloides (Abeta)
                                             Aβ42 y Aβ40 de Homo sapiens)], anticuerpo monoclonal
                                             humanizado;
                                             cadena pesada gamma4 (1-438) [VH humanizada (Homo sapiens
                                             IGHV3-23*04 (89.70%) -(IGHD)-IGHJ4*01 L123>T (107) [8.8.5] (1-
                                             112) -Homo sapiens IGHG4*01 bisagra S10>P (220) (113-438)],
                                             (126-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA
                                             humanizada (Homo sapiens IGKV2D-29*02 (86.00%) -IGKJ1*01)
                                             [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímero (218-
                                             218":221-221")-bisdisulfuro


                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             EVQLVESGGG LVQPGGSLRL SCAASGFTFS                  SYGMSWVRQA       PGKGLELVAS        50
                                             INSNGGSTYY PDSVKGRFTI SRDNAKNSLY                  LQMNSLRAED       TAVYYCASGD       100
                                             YWGQGTTVTV SSASTKGPSV FPLAPCSRST                  SESTAALGCL       VKDYFPEPVT       150
                                             VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV                  VTVPSSSLGT       KTYTCNVDHK       200
                                             PSNTKVDKRV ESKYGPPCPP CPAPEFLGGP                  SVFLFPPKPK       DTLMISRTPE       250
                                             VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK                  TKPREEQFNS       TYRVVSVLTV       300
                                             LHQDWLNGKE YKCKVSNKGL PSSIEKTISK                  AKGQPREPQV       YTLPPSQEEM       350
                                             TKNQVSLTCL VKGFYPSDIA VEWESNGQPE                  NNYKTTPPVL       DSDGSFFLYS       400
                                             RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ                  KSLSLSLG                          438

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIVMTQSPLS LPVTPGEPAS ISCRSSQSLV                  YSNGDTYLHW       YLQKPGQSPQ 50
                                             LLIYKVSNRF SGVPDRFSGS GSGTDFTLKI                  SRVEAEDVGV       YYCSQSTHVP 100
                                             WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                                             VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                                             VTHQGLSSPV TKSFNRGEC                                                          219

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96       139-195        253-313  359-417
                                                      22''-96'' 139''-195'' 253''-313'' 359''-417''
                                             Intra-L 23'-93'      139'-199'
                                                      23'''-93''' 139'''-199'''
                                             Inter-H-L 126-219' 126''-219'''
                                             Inter-H-H 218-218'' 221-221''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             289, 289''




 crenolanibum
 crenolanib                                  1-(2-{5-[(3-methyloxetan-3-yl)methoxy]-1H-benzimidazol-
                                             1-yl}quinolin-8-yl)piperidin-4-amine

 crénolanib                                  1-(2-{5-[(3-méthyloxétan-3-yl)méthoxy]-1H-benzimidazol-
                                             1-yl}quinoléin-8-yl)pipéridin-4-amine

 crenolanib                                  1-(2-{5-[(3-metiloxetan-3-il)metoxi]-1H-benzoimidazol-1-il}quinolin-
                                             8-il)piperidin-4-amina




                                                                                                                                         57
Recommended INN: List 67                                        WHO Drug Information, Vol. 26, No. 1, 2012


                           C26H29N5O2

                                   CH3
                                           O

                           O                                N        N

                                                       N                 N




                                                                         NH2



 dabrafenibum
 dabrafenib                N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-
                           2-fluorophenyl}-2,6-difluorobenzenesulfonamide

 dabrafénib                N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-
                           2-fluorophényl}-2,6-difluorobenzènesulfonamide

 dabrafenib                N-{3-[5-(2-aminopirimidin-4-il)-2-terc-butil-1,3-tiazol-4-il]-
                           2-fluorofenil}-2,6-difluorobencenosulfonamido

                           C23H20F3N5O2S2

                                                           NH2

                                                   N
                                                            N
                                       F
                                                   F                 S
                                           H                             CH3
                                           N
                                       S                         N
                               F    O O                              H3C CH3



 daclatasvirum
 daclatasvir               dimethyl N,N'-([1,1'-biphenyl]-4,4'-diylbis{1H-imidazole-5,2-diyl-
                           [(2S)-pyrrolidine-2,1-diyl][(1S)-3-methyl-1-oxobutane-
                           1,2-diyl]})dicarbamate

 daclatasvir               N,N'-([1,1'-biphényl]-4,4'-diylbis{1H-imidazole-5,2-diyl-
                           [(2S)-pyrrolidine-2,1-diyl][(1S)-3-méthyl-1-oxobutane-
                           1,2-diyl]})dicarbamate de diméthyle

 daclatasvir               N,N'-([1,1'-bifenil]-4,4'-diilbis{1H-imidazol-5,2-diil-[(2S)-pirrolidina-
                           2,1-diil][(1S)-3-metil-1-oxobutano-1,2-diil]})dicarbamato de dimetilo

                           C40H50N8O6

                                               CH3
                                     O         O                                                 N       O
                                   CH3                                               H
                                                                                     N                   H
                                           NH  N                                             H
                           H3C                                                                               CH3
                                             H                                           N    HN
                                   H                   N
                                                       H                                                 CH3
                                   O       N                                                 O       O
                                                                                             CH3




58
WHO Drug Information, Vol. 26, No. 1, 2012                                                            Recommended INN: List 67


 dalanterceptum #
 dalantercept                                fusion protein for immune applications (FPIA) comprising Homo
                                             sapiens ACVRL1 (activin A receptor type II-like 1, activin receptor-
                                             like kinase 1, ALK1, ALK-1, serine/threonine-protein kinase receptor
                                             R3, SKR3, transforming growth factor-beta superfamily receptor type
                                             I, TGF-B superfamily receptor type I, TSR-I, HHT2, ORW2)
                                             fragment, fused with Homo sapiens immunoglobulin G1 Fc fragment;
                                             ACVR2L1, 22-120 precursor fragment (1-99) -threonyl-triglycyl (100-
                                             103) -gamma1 chain H-CH2-CH3 fragment (104-328) [Homo
                                             sapiens IGHG1*03 hinge 8-15 (104-111), CH2 L1.3>A (115), G1>A
                                             (118), A115>V (211) (112-221), CH3 S85.3>P (284) (222-328)];
                                             (107-107':110-110')-bisdisulfide dimer

 dalantercept                                protéine de fusion pour applications immunitaires (FPIA) comprenant
                                             un fragment d'Homo sapiens ACVRL1 (récepteur 1 de type II-like de
                                             l'activine A, kinase 1 apparentée au récepteur de l'activine, ALK1,
                                             ALK-1, récepteur R3 de type sérine/thréonine-protéine kinase,
                                             SKR3, récepteur de type I de la superfamille du facteur de
                                             croissance transformant bêta, récepteur de type I de la superfamille
                                             du TGF-B, TSR-I, HHT2, ORW2), fusionné au fragment Fc de
                                             l'Homo sapiens immunoglobuline G1;
                                             ACVR2L1, fragment 22-120 du précurseur (1-99) -thréonyl-triglycyl
                                             (100-103) -fragment H-CH2-CH3 de la chaîne gamma1 (104-328)
                                             [Homo sapiens IGHG1*03 charnière 8-15 (104-111), CH2 L1.3>A
                                             (115), G1>A (118), A115>V (211) (112-221), CH3 S85.3>P (284)
                                             (222-328)]; dimère (107-107':110-110')-bisdisulfure

 dalantercept                                proteína de fusión para aplicaciones inmunitarias (FPIA) que
                                             comprende un fragmento de ACVRL1 de Homo sapiens (receptor 1
                                             de tipo II-like de la activina A, kinasa 1 relacionada con el receptor
                                             de la activina, ALK1, ALK-1, receptor R3 de tipo serina/treonina-
                                             proteinkinasa, SKR3, receptor de tipo I de la superfamilia del factor
                                             de crecimiento transformador beta, receptor de tipo I de la
                                             superfamilia del TGF-B, TSR-I, HHT2, ORW2), fusionada con el
                                             fragmento Fc de la inmunoglobulina G1 de Homo sapiens;
                                             ACVR2L1, fragmento 22-120 del precursor (1-99) -treonil-triglicil
                                             (100-103) -fragmento H-CH2-CH3 de la cadena gamma1 (104-328)
                                             [Homo sapiens IGHG1*03 bisagra 8-15 (104-111), CH2 L1.3>A
                                             (115), G1>A (118), A115>V (211) (112-221), CH3 S85.3>P (284)
                                             (222-328)]; dímero (107-107':110-110')-bisdisulfuro

                                             Fused chain / chaine fusionnée / cadena fusionada
                                             DPVKPSRGPL VTCTCESPHC KGPTCRGAWC TVVLVREEGR                        HPQEHRGCGN        50
                                             LHRELCRGRP TEFVNHYCCD SHLCNHNVSL VLEATQPPSE                        QPGTDGQLAT       100
                                             GGGTHTCPPC PAPEALGAPS VFLFPPKPKD TLMISRTPEV                        TCVVVDVSHE       150
                                             DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL                        HQDWLNGKEY       200
                                             KCKVSNKALP VPIEKTISKA KGQPREPQVY TLPPSREEMT                        KNQVSLTCLV       250
                                             KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGPFFLYSK                        LTVDKSRWQQ       300
                                             GNVFSCSVMH EALHNHYTQK SLSLSPGK                                                      328

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-chain 13-30 15-20 25-48 56-68 69-74 142-202 248-306
                                                          13'-30' 15'-20' 25'-48' 56'-68' 69'-74' 142'-202' 248'-306'
                                             Inter-chains 107-107' 110-110'

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             77, 178, 77', 178'




                                                                                                                                          59
Recommended INN: List 67                                    WHO Drug Information, Vol. 26, No. 1, 2012


 dasolampanelum
 dasolampanel              (3S,4aS,6S,8aR)-6-[3-chloro-2-(1H-tetrazol-5-yl)phenoxy]-
                           decahydroisoquinoline-3-carboxylic acid

 dasolampanel              acide (3S,4aS,6S,8aR)-6-[3-chloro-2-(1H-tétrazol-
                           5-yl)phénoxy]décahydroisoquinoléine-3-carboxylique

 dasolampanel              ácido (3S,4aS,6S,8aR)-6-[3-cloro-2-(1H-tetrazol-5-il)fenoxi]-
                           decahidroisoquinolina-3-carboxilico

                           C17H20ClN5O3

                                                        H
                                                                 NH

                           Cl               O                         CO2H
                                                H       H        H
                                N    NH
                                N   N

 delanzomibum
 delanzomib                {(1R)-1-[(2S,3R)-3-hydroxy-2-(6-phenylpyridine-
                           2-carboxamido)butanamido]-3-methylbutyl}boronic acid

 délanzomib                acide {(1R)-1-[(2S,3R)-3-hydroxy-2-(6-phénylpyridine-
                           2-carboxamido)butanamido]-3-méthylbutyl}boronique

 delanzomib                ácido {(1R)-1-[(2S,3R)-3-hidroxi-2-(6-fenilpiridina-
                           2-carboxamido)butanamido]-3-metilbutil}borónico

                           C21H28BN3O5

                                                    HO
                                                             CH3
                                                O H                      OH
                                                             H H
                                        N                      N         B
                                                    N                        OH
                                                    H                    H
                                                             O                CH3

                                                                         CH3

 delcasertibum
 delcasertib               human immunodeficiency virus 1 protein Tat-(46-57)-peptide (1→1')-
                           disulfide with L-cysteinyl-[mouse protein kinase C delta type-(8-17)-
                           peptide]

 delcasertib               protéine Tat du virus 1 de l'immunodéficience humaine-(46-57)-
                           peptide (1→1')-disulfure avec le L-cystéinyl-(protéine kinase C type
                           delta de souris-(8-17)-peptide

 delcasertib               proteína Tat del virus 1 de la inmunodeficiencia humana-(46-57)-
                           péptido (1→1')-disulfuro con la L-cisteinil-[proteína kinasa C tipo
                           delta de ratón-(8-17)-péptido]




60
WHO Drug Information, Vol. 26, No. 1, 2012                                                      Recommended INN: List 67


                                             C120H199N45O34S2

                                             A chain / Chaîne A / Cadena A
                                             CYGRKKRRQR RR              12

                                             Light chain / Chaîne légère / Cadena ligera
                                             CSFNSYELGS L                 11'

                                             Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro
                                             1-1'




 dolutegravirum
 dolutegravir                                (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-
                                             6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-
                                             b][1,3]oxazine-9-carboxamide

 dolutégravir                                (4R,12aS)-N-[(2,4-difluorophényl)méthyl]-7-hydroxy-4-méthyl-
                                             6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-
                                             b][1,3]oxazine-9-carboxamide

 dolutegravir                                (4R,12aS)-N-[(2,4-difluorofenil)metil]-7-hidroxi-4-metil-6,8-dioxo-
                                             3,4,6,8,12,12a-hexahidro-2H-pirido[1',2':4,5]pirazino[2,1-
                                             b][1,3]oxazina-9-carboxamida

                                             C20H19F2N3O5

                                              H       CH3 O       OH
                                                                         O       F         F
                                                       N
                                                                             H
                                                              N              N
                                                  O
                                                       H
                                                                         O



 encaleretum
 encaleret                                   2′-{(1R)-1-[(2R)-3-{[1-(4-chloro-3-fluorophenyl)-2-methylpropan-
                                             2-yl]amino}-2-hydroxypropoxy]ethyl}-3-methyl[1,1′-biphenyl]-
                                             4-carboxylic acid

 encaléret                                   acide 2′-{(1R)-1-[(2R)-3-{[1-(4-chloro-3-fluorophényl)-
                                             2-méthylpropan-2-yl]amino}-2-hydroxypropoxy]éthyl}-3-méthyl[1,1′-
                                             biphényl]-4-carboxylique

 encaleret                                   ácido 2′-{(1R)-1-[(2R)-3-{[1-(4-cloro-3-fluorofenil)-2-metilpropan-
                                             2-yl]amino}-2-hidroxipropoxi]etil}-3-metil[1,1′-bifenil]-4-carboxílico

                                             C29H33ClFNO4



                                             Cl                                                        CH3
                                                              H3C      CH3
                                                                                           H
                                              F                         N            O                 CO2H
                                                                        H                CH3
                                                                             H OH




                                                                                                                                61
Recommended INN: List 67                                 WHO Drug Information, Vol. 26, No. 1, 2012


 epelsibanum
 epelsiban                 (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethylpyridin-
                           3-yl)-2-(morpholin-4-yl)-2-oxoethyl]-6-[(2S)-butan-2-yl]piperazine-
                           2,5-dione

 épelsiban                 (3R,6R)-3-(2,3-dihydro-1H-indén-2-yl)-1-[(1R)-1-(2,6-diméthylpyridin-
                           3-yl)-2-(morpholin-4-yl)-2-oxoéthyl]-6-[(2S)-butan-2-yl]pipérazine-
                           2,5-dione

 epelsibán                 (3R,6R)-3-(2,3-dihidro-1H-inden-2-il)-1-[(1R)-1-(2,6-dimetilpiridin-
                           3-il)-2-(morfolin-4-il)-2-oxoetil]-6-[(2S)-butan-2-il]piperazina-2,5-diona

                           C30H38N4O4

                                                      CH3 CH3
                                              O H

                                         HN             H O
                                                  N
                                                              N
                                         H
                                              O     H               O
                                              H3C
                                                        N
                                                              CH3



 etoxybamidum
 etoxybamide               4-hydroxy-N-(2-hydroxyethyl)butanamide

 étoxybamide               4-hydroxy-N-(2-hydroxyéthyl)butanamide

 etoxibamida               4-hidroxi-N-(2-hidroxietil)butanamida

                           C6H13NO3

                                          O
                           HO                            OH
                                              N
                                              H



 evacetrapibum
 evacetrapib               (1r,4r)-4-({(5S)-5-[{[3,5-bis(trifluoromethyl)phenyl]methyl}(2-methyl-
                           2H-tetrazol-5-yl)amino]-7,9-dimethyl-2,3,4,5-tetrahydro-
                           1H-1-benzazepin-1-yl}methyl)cyclohexane-1-carboxylic acid

 évacétrapib               acide (1r,4r)-4-({(5S)-5-[{[3,5-bis(trifluorométhyl)phényl]méthyl}(2-
                           méthyl-2H-tétrazol-5-yl)amino]-7,9-diméthyl-2,3,4,5-tétrahydro-
                           1H-benzazépin-1-yl}méthyl)cyclohexane-1-carboxylique

 evacetrapib               ácido (1r,4r)-4-({(5S)-5-[{[3,5-bis(trifluorometil)fenil]metil}(2-metil-
                           2H-tetrazol-5-il)amino]-7,9-dimetil-2,3,4,5-tetrahidro-
                           1H-1-benzazepin-1-il}metil)ciclohexano-1-carboxílico




62
WHO Drug Information, Vol. 26, No. 1, 2012                                                            Recommended INN: List 67


                                             C31H36F6N6O2

                                                              H3C                 CH3


                                                                                  N
                                                                    H                 H               H
                                             F3C
                                                                    N                                 CO2H

                                                                N       N
                                                        CF3     N N
                                                                        CH3



 exeporfinii chloridum
 exeporfinium chloride                       3,3'-(21H,23H-porphyrin-5,15-diylbis{[(4,1-phenylene)oxy]-
                                             N,N,N-trimethylpropan-1-aminium}) dichloride

 chlorure d'exéporfinium                     dichlorure de 3,3'-[21H,23H-porphyrin-5,15-diylbis(4,1-
                                             phénylèneoxy)]bis[N,N,N-triméthylpropan-1-aminium]

 cloruro de exeporfinio                      dicloruro de 3,3'-(21H,23H-porfirin-5,15-diilbis{[(4,1-fenileno)oxi]-
                                             N,N,N-trimetilpropan-1-aminium})

                                             C44H50Cl2N6O2

                                                                                                             O

                                                   Cl
                                                                                          N
                                                    CH3                                   H
                                             H3C                                  N                          H3C       N
                                                   N CH3                                      N                            CH3
                                                                                      H                          H3C
                                                                                      N
                                                                                                                   Cl
                                                            O



 fabomotizolum
 fabomotizole                                5-ethoxy-2-{[2-(morpholin-4-yl)ethyl]sulfanyl}-1H-benzimidazole

 fabomotizole                                5-éthoxy-2-{[2-(morpholin-4-yl)éthyl]sulfanyl}-1H-benzimidazole

 fabomotizol                                 5-etoxi-2-{[2-(morfolin-4-il)etil]sulfanil}-1H-benzoimidazol

                                             C15H21N3O2S


                                                        O               NH                        O
                                             H3C
                                                                                          N
                                                                    N         S



 faciniclinum
 facinicline                                 N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-1H-indazole-3-carboxamide

 facinicline                                 N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-1H-indazole-3-carboxamide

 faciniclina                                 N-[(3S)-1-azabiciclo[2.2.2]octan-3-il]-1H-indazol-3-carboxamida




                                                                                                                                 63
Recommended INN: List 67                              WHO Drug Information, Vol. 26, No. 1, 2012


                           C15H18N4O

                              N
                                         O
                                     H
                                     N
                                     H
                                             N NH


 fiboflaponum
 fiboflapon                3-{3-(tert-butylsulfanyl)-1-{[4-(6-ethoxypyridin-3-yl)phenyl]methyl}-
                           5-[(5-methylpyridin-2-yl)methoxy]-1H-indol-2-yl}-
                           2,2-dimethylpropanoic acid

 fiboflapon                acide 3-{3-(tert-butylsulfanyl)-1-{[4-(6-éthoxypyridin-
                           3-yl)phényl]méthyl}-5-[(5-méthylpyridin-2-yl)méthoxy]-1H-indol-2-yl}-
                           2,2-diméthylpropanoïque

 fiboflapón                ácido 3-{3-(terc-butilsulfanil)-1-{[4-(6-etoxipiridin-3-il)fenil]metil}-
                           5-[(5-metilpiridin-2-il)metoxi]-1H-indol-2-yl}-2,2-dimetilpropanoico

                           C38H43N3O4S

                           H3C       O       N




                                                                       CH3
                                                                H 3C
                                                            N            CO2H



                                     N           O              S
                                                      H3C
                                                              CH3
                                                            CH3
                              H 3C



 ficlatuzumabum #
 ficlatuzumab              immunoglobulin G1-kappa, anti-[Homo sapiens HGF (hepatocyte
                           growth factor, scatter factor, SF, hepatopoeitin A)], humanized
                           monoclonal antibody;
                           gamma1 heavy chain (1-448) [humanized VH (Homo sapiens
                           IGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01 V124>L (114)) [8.8.11]
                           (1-118) -Homo sapiens IGHG1*03 (119-448)], (221-214')-disulfide
                           with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens
                           IGKV4-1*01 (73.30%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens
                           IGKC*01 (108'-214')]; (227-227":230-230")-bisdisulfide dimer

 ficlatuzumab              immunoglobuline G1-kappa, anti-[Homo sapiens HGF (facteur de
                           croissance de l'hépatocyte, facteur dispersant, SF, hépatopoïétine
                           A)], anticorps monoclonal humanisé;
                           chaîne lourde gamma1 (1-448) [VH humanisé (Homo sapiens
                           IGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01 V124>L (114)) [8.8.11]
                           (1-118) -Homo sapiens IGHG1*03 (119-448)], (221-214')-disulfure
                           avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo
                           sapiens IGKV4-1*01 (73.30%) -IGKJ2*01) [6.3.9] (1'-107') -Homo
                           sapiens IGKC*01 (108'-214')]; dimère (227-227":230-230")-
                           bisdisulfure




64
WHO Drug Information, Vol. 26, No. 1, 2012                                                           Recommended INN: List 67


 ficlatuzumab                                inmunoglobulina G1-kappa, anti-[HGF de Homo sapiens (factor de
                                             crecimiento del hepatocito, factor dispersante, SF, hepatopoyetina
                                             A)], anticuerpo monoclonal humanizado;
                                             cadena pesada gamma1 (1-448) [VH humanizado (Homo sapiens
                                             IGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01 V124>L (114)) [8.8.11]
                                             (1-118) -Homo sapiens IGHG1*03 (119-448)], (221-214')-disulfuro
                                             con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (Homo
                                             sapiens IGKV4-1*01 (73.30%) -IGKJ2*01) [6.3.9] (1'-107') -Homo
                                             sapiens IGKC*01 (108'-214')]; dímero (227-227":230-230")-
                                             bisdisulfuro

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLVQPGAE VKKPGTSVKL SCKASGYTFT                  TYWMHWVRQA       PGQGLEWIGE        50
                                             INPTNGHTNY NQKFQGRATL TVDKSTSTAY                  MELSSLRSED       TAVYYCARNY       100
                                             VGSIFDYWGQ GTLLTVSSAS TKGPSVFPLA                  PSSKSTSGGT       AALGCLVKDY       150
                                             FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSSLGTQTYI       200
                                             CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC                  PAPELLGGPS       VFLFPPKPKD       250
                                             TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                  DGVEVHNAKT       KPREEQYNST       300
                                             YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                  APIEKTISKA       KGQPREPQVY       350
                                             TLPPSREEMT KNQVSLTCLV KGFYPSDIAV                  EWESNGQPEN       NYKTTPPVLD       400
                                             SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                  EALHNHYTQK       SLSLSPGK         448

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIVMTQSPDS LAMSLGERVT LNCKASENVV                  SYVSWYQQKP       GQSPKLLIYG 50
                                             ASNRESGVPD RFSGSGSATD FTLTISSVQA                  EDVADYHCGQ       SYNYPYTFGQ 100
                                             GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96 145-201              262-322  368-426
                                                      22''-96'' 145''-201'' 262''-322'' 368''-426''
                                             Intra-L 23'-88'      134'-194'
                                                      23'''-88''' 134'''-194'''
                                             Inter-H-L 221-214' 221''-214'''
                                             Inter-H-H 227-227'' 230-230''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             298, 298''



 galeteronum
 galeterone                                  17-(1H-benzimidazol-1-yl)androsta-5,16-dien-3β-ol

 galétérone                                  17-(1H-benzimidazol-1-yl)androsta-5,16-dién-3β-ol

 galeterona                                  17-(1H-benzoimidazol-1-il)androsta-5,16-dien-3β-ol

                                             C26H32N2O
                                                                             N


                                                                       CH3 N

                                                           CH3     H

                                                               H       H
                                             HO
                                                  H

 ganetespibum
 ganetespib                                  5-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-4-(1-methyl-1H-indol-5-yl)-
                                             2,4-dihydro-3H-1,2,4-triazol-3-one

 ganétespib                                  5-[2,4-dihydroxy-5-(propan-2-yl)phényl]-4-(1-méthyl-1H-indol-5-yl)-
                                             2,4-dihydro-3H-1,2,4-triazol-3-one

 ganetespib                                  5-[2,4-dihidroxi-5-(propan-2-il)fenil]-4-(1-metil-1H-indol-5-il)-
                                             2,4-dihidro-3H-1,2,4-triazol-3-ona



                                                                                                                                         65
Recommended INN: List 67                                     WHO Drug Information, Vol. 26, No. 1, 2012


                               C20H20N4O3


                                 H3 C     N

                                                         O
                                      CH3       N
                                                         NH
                               H3C                   N

                                     HO         OH

 indatuximabum ravtansinum #
 indatuximab ravtansine        immunoglobulin G4-kappa, anti-[Homo sapiens SDC1 (syndecan-1,
                               CD138)], chimeric monoclonal antibody conjugated to maytansinoid
                               DM4;
                               gamma4 heavy chain (1-449) [Mus musculus VH (IGHV1-9*01 -
                               (IGHD)-IGHJ4*01) [8.8.15] (1-122) -Homo sapiens IGHG4*01 (123-
                               449)], (136-214')-disulfide with kappa light chain (1'-214') [Mus
                               musculus V-KAPPA (IGKV10-94*01 -IGKJ1*01) [6.3.9] (1'-107') -
                               Homo sapiens IGKC*01 (108'-214')]; (228-228'':231-231'')-
                               bisdisulfide dimer; conjugated, on an average of 3 to 4 lysyl, to
                                                     2'            2'
                               maytansinoid DM4 [N -deacetyl-N -(4-mercapto-4-methyl-
                               1-oxopentyl)-maytansine] via the reducible SPDB linker
                               [N-succinimidyl 4-(2-pyridyldithio)butanoate]
                               For the ravtansine part, please refer to the document "INN for
                               pharmaceutical substances: Names for radicals, groups and others"*

 indatuximab ravtansine        immunoglobuline G4-kappa, anti-[Homo sapiens SDC1 (syndecan-1,
                               CD138)], anticorps monoclonal chimérique conjugué au
                               maytansinoïde DM4;
                               chaîne lourde gamma4 (1-449) [Mus musculus VH (IGHV1-9*01 -
                               (IGHD)-IGHJ4*01) [8.8.15] (1-122) -Homo sapiens IGHG4*01 (123-
                               449)], (136-214')-disulfure avec la chaîne légère kappa (1'-214')
                               [Mus musculus V-KAPPA (IGKV10-94*01 -IGKJ1*01) [6.3.9] (1'-107')
                               -Homo sapiens IGKC*01 (108'-214')]; dimère (228-228":231-231")-
                               bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au
                                                       2'           2'
                               maytansinoïde DM4 [N -déacétyl-N -(4-mercapto-4-méthyl-
                               1-oxopentyl)-maytansine] via le linker SPDB réductible
                               [4-(2-pyridyldithio)butanoate de N-succinimidyle]
                               Pour la partie ravtansine, veuillez vous référer au document "INN for
                               pharmaceutical substances: Names for radicals, groups and
                               others"*.

 indatuximab ravtansina        inmunoglobulina G4-kappa, anti-[SDC1 de Homo sapiens (sindecán-
                               1, CD138)], anticuerpo monoclonal quimérico conjugado con el
                               maitansinoide DM4;
                               cadena pesada gamma4 (1-449) [Mus musculus VH (IGHV1-9*01 -
                               (IGHD)-IGHJ4*01) [8.8.15] (1-122) -Homo sapiens IGHG4*01 (123-
                               449)], (136-214')-disulfuro con la cadena ligera kappa (1'-214') [Mus
                               musculus V-KAPPA (IGKV10-94*01 -IGKJ1*01) [6.3.9] (1'-107') -
                               Homo sapiens IGKC*01 (108'-214')]; dímero (228-228":231-231")-
                               bisdisulfuro; conjugado, en 3-4 grupos lisil por término medio con el
                                                        2'          2'
                               maitansinoide DM4 [N -desacetil-N -(4-mercapto-4-metil-
                               1-oxopentil)-maitansina] mediante el espaciador SPDB reducible
                               [4-(2-piridilditio)butanoato de N-succinimidilo]
                               Para la fracción ravtansina, se ruega referirse al documento "INN for
                               pharmaceutical substances: Names for radicals, groups and others"*




66
WHO Drug Information, Vol. 26, No. 1, 2012                                                            Recommended INN: List 67




                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLQQSGSE LMMPGASVKI SCKATGYTFS                   NYWIEWVKQR      PGHGLEWIGE        50
                                             ILPGTGRTIY NEKFKGKATF TADISSNTVQ                   MQLSSLTSED      SAVYYCARRD       100
                                             YYGNFYYAMD YWGQGTSVTV SSASTKGPSV                   FPLAPCSRST      SESTAALGCL       150
                                             VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ                   SSGLYSLSSV      VTVPSSSLGT       200
                                             KTYTCNVDHK PSNTKVDKRV ESKYGPPCPS                   CPAPEFLGGP      SVFLFPPKPK       250
                                             DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY                   VDGVEVHNAK      TKPREEQFNS       300
                                             TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL                   PSSIEKTISK      AKGQPREPQV       350
                                             YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA                   VEWESNGQPE      NNYKTTPPVL       400
                                             DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM                   HEALHNHYTQ      KSLSLSLGK        449

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIQMTQSTSS LSASLGDRVT ISCSASQGIN                   NYLNWYQQKP      DGTVELLIYY 50
                                             TSTLQSGVPS RFSGSGSGTD YSLTISNLEP                   EDIGTYYCQQ      YSKLPRTFGG 100
                                             GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                   SVVCLLNNFY      PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                   LSKADYEKHK      VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96        149-205       263-323  369-437
                                                       22''-96'' 149''-205'' 263''-323'' 369''-437''
                                             Intra-L 23'-88'      134'-194'
                                                      23'''-88''' 134'''-194'''
                                             Inter-H-L 136-214' 136''-214'''
                                             Inter-H-H 228-228'' 231-231''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             299, 299''


                     123
 iofolastatum (            I)
             123
 iofolastat ( I)                             N-{[(1S)-1-carboxy-5-{[(4-
                                              123
                                             ( I)iodophenyl)methyl]amino}pentyl]carbamoyl}-L-glutamic acid
              123
 iofolastat (   I)                           acide N-{[(1S)-1-carboxy-5-{[(4-
                                              123
                                             ( I)iodophényl)méthyl]amino}pentyl]carbamoyl}-L-glutamique
              123
 iofolastat (   I)                           ácido N-{[(1S)-1-carboxi-5-{[(4-
                                              123
                                             ( I)iodofenil)metil]amino}pentil]carbamoil}-L-glutámico
                                                     123
                                             C19H26     IN3O7

                                                              NH                                CO2H

                                                                                H       O   H

                                             123                    HO2C          N         N       CO2H
                                                I                                 H         H

 irdabisantum
 irdabisant                                  6-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)pyridazin-3(2H)-
                                             one

 irdabisant                                  6-(4-{3-[(2R)-2-méthylpyrrolidin-1-yl]propoxy}phényl)pyridazin-3(2H)-
                                             one

 irdabisant                                  6-(4-{3-[(2R)-2-metilpirrolidin-1-il]propoxi}fenil)piridazin-3(2H)-ona

                                             C18H23N3O2

                                                                                        H
                                                                                        N       O
                                                                                    N




                                                    N              O

                                                        CH3
                                                    H


                                                                                                                                          67
Recommended INN: List 67                                     WHO Drug Information, Vol. 26, No. 1, 2012




 ixekizumabum #
 ixekizumab                immunoglobulin G4-kappa, anti-[Homo sapiens IL17A (interleukin
                           17A, IL-17A)], humanized monoclonal antibody;
                           gamma4 heavy chain (1-445) [humanized VH (Homo sapiens
                           IGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo
                           sapiens IGHG4*01 hinge S10>P (227), CH3 K130>del (120-445)],
                           (133-219')-disulfide with kappa light chain (1'-219') [humanized
                           V-KAPPA (Homo sapiens IGKV2D-29*02 (89.00%) -IGKJ2*01)
                           [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; (225-
                           225":228-228")-bisdisulfide dimer

 ixékizumab                immunoglobuline G4-kappa, anti-[Homo sapiens IL17A (interleukine
                           17A, IL-17A)], anticorps monoclonal humanisé;
                           chaîne lourde gamma4 (1-445) [VH humanisé (Homo sapiens
                           IGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo
                           sapiens IGHG4*01 charnière S10>P (227), CH3 K130>del (120-
                           445)], (133-219')-disulfure avec la chaîne légère kappa (1'-219')
                           [V-KAPPA humanisé (Homo sapiens IGKV2D-29*02 (89.00%) -
                           IGKJ2*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')];
                           dimère (225-225":228-228")-bisdisulfure

 ixekizumab                inmunoglobulina G4-kappa, anti-[Homo sapiens IL17A (interleukina
                           17A, IL-17A)], anticuerpo monoclonal humanizado;
                           cadena pesada gamma4 (1-445) [VH humanizada (Homo sapiens
                           IGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo
                           sapiens IGHG4*01 bisagra S10>P (227), CH3 K130>del (120-445)],
                           (133-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA
                           humanizada (Homo sapiens IGKV2D-29*02 (89.00%) -IGKJ2*01)
                           [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímero (225-
                           225":228-228")-bisdisulfuro

                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGSSVKV SCKASGYSFT                  DYHIHWVRQA       PGQGLEWMGV        50
                           INPMYGTTDY NQRFKGRVTI TADESTSTAY                  MELSSLRSED       TAVYYCARYD       100
                           YFTGTGVYWG QGTLVTVSSA STKGPSVFPL                  APCSRSTSES       TAALGCLVKD       150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTKTY       200
                           TCNVDHKPSN TKVDKRVESK YGPPCPPCPA                  PEFLGGPSVF       LFPPKPKDTL       250
                           MISRTPEVTC VVVDVSQEDP EVQFNWYVDG                  VEVHNAKTKP       REEQFNSTYR       300
                           VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS                  IEKTISKAKG       QPREPQVYTL       350
                           PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW                  ESNGQPENNY       KTTPPVLDSD       400
                           GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA                  LHNHYTQKSL       SLSLG            445

                           Light chain / Chaîne légère / Cadena ligera
                           DIVMTQTPLS LSVTPGQPAS ISCRSSRSLV                  HSRGNTYLHW       YLQKPGQSPQ 50
                           LLIYKVSNRF IGVPDRFSGS GSGTDFTLKI                  SRVEAEDVGV       YYCSQSTHLP 100
                           FTFGQGTKLE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                           VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                           VTHQGLSSPV TKSFNRGEC                                                          219

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        146-202       260-320  366-424
                                     22''-96'' 146''-202'' 260''-320'' 366''-424''
                           Intra-L 23'-93'      139'-199'
                                    23'''-93''' 139'''-199'''
                           Inter-H-L 133-219' 133''-219'''
                           Inter-H-H 225-225'' 228-228''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           296, 296''



 ladarixinum
 ladarixin                 4-[(2R)-1-oxo-1-(methanesulfonamido)propan-2-yl]phenyl
                           trifluoromethanesulfonate

 ladarixine                trifluorométhanesulfonate de 4-[(2R)-1-oxo-
                           1-(méthanesulfonamido)propan-2-yl]phényle




68
WHO Drug Information, Vol. 26, No. 1, 2012                                                               Recommended INN: List 67




 ladarixina                                  trifluoromethanesulfonato de 4-[(2R)-1-oxo-
                                             1-(metanosulfonamido)propan-2-il]fenil

                                             C11H12F3NO6S2

                                                                      H CH3
                                                                                   H
                                                                                   N       CH3
                                                O O                                    S
                                                     S                        O    O O
                                             F3C         O



 lenomorelinum
                                              3.26
 lenomorelin                                 O -octanoylhuman appetite-regulating hormone (growth hormone-
                                             releasing peptide) precursor (protein M46)-(24-51)-peptide (ghrelin-
                                             28-C8)
                                              3.26
 lénomoréline                                O -octanoylprécurseur de l'hormone humaine de régulation de
                                             l'appétit (précurseur du peptide de libération d'hormone de
                                             croissance, protéine M46)-(24-51)-peptide (ghréline-28-C8)
                                              3.26
 lenomorelina                                O -octanoilprecursor de la hormona humana de regulación del
                                             apetito (precursor del péptido de liberación de hormona del
                                             crecimiento, proteína M46)-(24-51)-péptido (ghrelina-28-C8)

                                             C149H249N47O42

                                             GSSFLSPEHQ RVQQRKESKK PPAKLQPR                                28

                                             Modified residue / Résidu modifié / Residuo modificado
                                                        S                                            O
                                                        3
                                                O-octanoyl-L-seryl                     H         O                     CH3
                                                O-octanoyl-L-séryl
                                                O-octanoil-L-serilo                    N    C
                                                                                       H
                                                                                            O



 lesinuradum
 lesinurad                                   2-{[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-
                                             3-yl]sulfanyl}acetic acid

 lésinurad                                   acide 2-{[5-bromo-4-(4-cyclopropylnaphtalén-1-yl)-4H-1,2,4-triazol-
                                             3-yl]sulfanyl}acétique

 lesinurad                                   ácido 2-{[5-bromo-4-(4-ciclopropilnaftalen-1-il)-4H-1,2,4-triazol-
                                             3-il]sulfanil}acético

                                             C17H14BrN3O2S

                                                             Br
                                                                      N
                                                                          N
                                                                  N
                                                                                  CO2H
                                                                      S




                                                                                                                               69
Recommended INN: List 67                                    WHO Drug Information, Vol. 26, No. 1, 2012


 lexibulinum
 lexibulin                 1-ethyl-3-[2-methoxy-4-(5-methyl-4-{[(1S)-1-(pyridin-
                           3-yl)butyl]amino}pyrimidin-2-yl)phenyl]urea

 lexibuline                1-éthyl-3-[2-méthoxy-4-(5-méthyl-4-{[(1S)-1-(pyridin-
                           3-yl)butyl]amino}pyrimidin-2-yl)phényl]urée

 lexibulina                1-etil-3-[2-metoxi-4-(5-metil-4-{[(1S)-1-(piridin-
                           3-il)butil]amino}pirimidin-2-il)fenil]urea

                           C24H30N6O2

                           H3C          H3C
                                         H             N

                           N               N       N                       O
                                           H
                                                                       N       N       CH3
                                                                       H       H
                                                                OCH3

 lipegfilgrastimum #
 lipegfilgrastim           pegylated granulocyte colony stimulating factor;
                             3.133    5
                           O       -[N -(N-{[ω-methoxypoly(oxyethylene)]carbonyl}glycyl)-
                           α-neuraminyl-(2→6)-α-D-galactopyranosyl]-L-methionyl-
                           des-1-L-alanine-des-37-L-valine-des-38-L-serine-des-39-L-glutamic
                           acid-human granulocyte colony-stimulating factor (G-CSF,
                           pluripoietin)

 lipegfilgrastim           facteur de stimulation de colonie de granulocytes humain pégylé;
                             3.133    5
                           O       -[N -(N-{[ω-méthoxypoly(oxyéthylène)]carbonyl}glycyl)-
                           α-neuraminyl-(2→6)-α-D-galactopyranosyl]-L-méthionyl-
                           dès-1-L-alanine-dès-37-L-valine-des-38-L-sérine-dès-39-L-acide
                           glutamique-facteur de stimulation de colonie de granulocytes humain
                           (G-CSF, pluripoïétine)

 lipegfilgrastim           factor de estimulación de colonias de granulocitos humano pegilado;
                             3.133    5
                           O       -[N -(N-{[ω-metoxipoli(oxietileno)]carbonil}glicil)-α-neuraminil-
                           (2→6)-α-D-galactopiranosil]-L-metionil-des-1-L-alanina-
                           des-37-L-valina-des-38-L-serine-des-39-L-ácido glutámico-factor de
                           estimulación de colonias de granulocitos humanos (G-CSF,
                           pluripoyetina)

                           C864H1369N225O258S9 [C2H4O]n

                                                                                           M 0
                           TPLGPASSLP      QSFLLKCLEQ       VRKIQGDGAA LQEKLCATYK LCHPEELVLL 50
                           GHSLGIPWAP      LSSCPSQALQ       LAGCLSQLHS GLFLYQGLLQ ALEGISPELG 100
                           PTLDTLQLDV      ADFATTIWQQ       MEELGMAPAL QPTQGAMPAF ASAFQRRAGG 150
                           VLVASHLQSF      LEVSYRVLRH       LAQP                             174

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           36-42 64-74

                           Modified residue / Résidu modifié / Residuo modificado
                                    T                       HO             OH
                                   133                                               CO2H
                            PEG-Gly-Neu-Gal-Thr                                O
                                                                 HO H                  O
                                                                                                  O                CH3
                                                                     HN              HO                    O        H
                                                                H
                                     H3C                O       N              OH
                                             O                             O                                   N     C
                                                        n                                  HO         OH       H
                                                            O                                                        O




70
WHO Drug Information, Vol. 26, No. 1, 2012                                                Recommended INN: List 67


 lorediplonum
 lorediplon                                  N-{2-fluoro-5-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-
                                             7-yl]phenyl}-N-methylacetamide

 lorédiplon                                  N-{2-fluoro-5-[3-(thiophéne-2-carbonyl)pryrazolo[1,5-a]pyrimidin-
                                             7-yl]phényl}-N-méthylacétamide

 lorediplón                                  N-{2-fluoro-5-[3-(tiofeno-2-carbonil)pirazolo[1,5-a]pirimidin-7-il]fenil}-
                                             N-metilacetamida

                                             C20H15FN4O2S

                                                                        O


                                                                                S
                                                                N
                                                       CH3          N       N
                                             H3C       N

                                                   O
                                                       F

 lumacaftorum
 lumacaftor                                  3-{6-[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-
                                             1-carboxamido]-3-methylpyridin-2-yl}benzoic acid

 lumacaftor                                  acide 3-{6-[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-
                                             1-carboxamido]-3-methylpyridin-2-yl}benzoïque

 lumacaftor                                  ácido 3-{6-[1-(2,2-difluoro-1,3-benzodioxol-5-il)ciclopropano-
                                             1-carboxamido]-3-metilpiridin-2-il}benzoico

                                             C24H18F2N2O5


                                                                        H
                                                   O                    N       N
                                             F                                              CO2H
                                             F                      O
                                                   O                                CH3


 lurbinectedinum
 lurbinectedin                               (1'R,6R,6aR,7R,13S,14S,16R)-8,14-dihydroxy-6',9-dimethoxy-
                                             4,10,23-trimethyl-19-oxo-2',3',4',6,7,9',12,13,14,16-decahydro-
                                             6aH-spiro[7,13-azano-6,16-
                                             (epithiopropanooxymethano)[1,3]dioxolo[7,8]isoquinolino[3,2-
                                             b][3]benzazocine-20,1'-pyrido[3,4-b]indol]-5-yl acetate

 lurbinectédine                              acétate de (1'R,6R,6aR,7R,13S,14S,16R)-8,14-dihydroxy-
                                             6',9-diméthoxy-4,10,23-triméthyl-19-oxo-2',3',4',6,7,9',12,13,14,16-
                                             décahydro-6aH-spiro[7,13-azano-6,16-
                                             (épithiopropanooxyméthano)[1,3]dioxolo[7,8]isoquinolino[3,2-
                                             b][3]benzazocine-20,1'-pyrido[3,4-b]indol]-5-yl

 lurbinectedina                              acetato de (1'R,6R,6aR,7R,13S,14S,16R)-8,14-dihidroxi-
                                             6',9-dimetoxi-4,10,23-trimetil-19-oxo-2',3',4',6,7,9',12,13,14,16-
                                             decahidro-16H-spiro[7,13-azano-6,16-
                                             (epitiopropanooximetano)[1,3]dioxolo[7,8]isoquinolino[3,2-
                                             b][3]benzazocina-20,1'-pirido[3,4-b]indol]-5-ilo




                                                                                                                          71
Recommended INN: List 67                                      WHO Drug Information, Vol. 26, No. 1, 2012




                            C41H44N4O10S

                                                          OH                   O
                                                      H                H
                                              H                                        O
                                                               N
                                                          O
                                                  N                                    CH3
                                            H3C                H           S
                                                                   H           O       CH3
                                                       H
                                                      O
                                                        H                          O
                                                        N
                            H3C               OH                       NH
                                     OCH3


                                            H3CO




 melphalanum flufenamidum
 melphalan flufenamide      ethyl (2S)-2-[(2S)-2-amino-3-{4-[bis(2-
                            chloroethyl)amino]phenyl}propanamido]-
                            3-(4-fluorophenyl)propanoate

 melphalan flufénamide      (2S)-2-[(2S)-2-amino-3-{4-[bis(2-
                            chloroéthyl)amino]phényl}propanamido]-
                            3-(4-fluorophényl)propanoate d'éthyle

 melfalán flufenamida       (2S)-2-[(2S)-2-amino-3-{4-[bis(2-cloroetil)amino]fenil}propanamido]-
                            3-(4-fluorofenil)propanoato de etilo

                            C24H30Cl2FN3O3

                                   Cl



                                        N
                            Cl                            H NH2                    O
                                                                       H
                                                                       N
                                                                                       O     CH3
                                                                   O   H




                                                                   F




 mericitabinum
 mericitabine               (2'R)-2'-deoxy-2'-fluoro-2'-methyl-2',3'-bis-
                            O-(2-methylpropanoyl)cytidine

 méricitabine               3',5'-bis(2-méthylpropanoate) de (2'R)-2'-déoxy-2'-fluoro-
                            2'-méthylcytidine

 mericitabina               (2'R)-2'-desoxi-2'-fluoro-2'-metil-2',3'-bis-O-(2-metilpropanoil)citidina




72
WHO Drug Information, Vol. 26, No. 1, 2012                                                               Recommended INN: List 67


                                             C18H26FN3O6

                                                                              NH2
                                                   CH3
                                                             O           N
                                             H3C
                                                        O            O        N
                                                                     O
                                                                     H3C
                                                        CH3
                                                                 O       F
                                                  H3C
                                                             O



 milciclibum
 milciclib                                   N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-
                                             4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide

 milciclib                                   N,1,4,4-tétraméthyl-8-{[4-(4-méthylpipérazin-1-yl)phényl]amino}-
                                             4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide

 milciclib                                   N,1,4,4-tetrametil-8-{[4-(4-metilpiperazin-1-il)fenil]amino}-4,5-dihidro-
                                             1H-pirazolo[4,3-h]quinazolina-3-carboxamida

                                             C25H32N8O

                                                                                            H 3C
                                                                                                   N N      H
                                                                              H                             N CH
                                                                                                                3
                                                                              N         N
                                                                                                         O
                                                                                    N                 CH3
                                                             N
                                                                                                     CH3
                                                   N
                                             H3C



 naldemedinum
 naldemedine                                 17-(cyclopropylmethyl)-6,7-didehydro-4,5α-epoxy-3,6,14-trihydroxy-
                                             N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-
                                             7-carboxamide

 naldémédine                                 17-(cyclopropylméthyl)-6,7-didéhydro-4,5α-époxy-3,6,14-trihydroxy-
                                             N-[2-(3-phényl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-
                                             7-carboxamide

 naldemedina                                 17-(ciclopropilmetil)-6,7-didehidro-4,5α-epoxi-3,6,14-trihidroxi-
                                             N-[2-(3-fenil-1,2,4-oxadiazol-5-il)propan-2-il]morfinan-7-carboxamida

                                             C32H34N4O6

                                                         H       N
                                                                                        N
                                                        HO                     O    O
                                                                                             N
                                                                              HN
                                                            O                         CH3
                                             HO                  H       OH         CH3




                                                                                                                               73
Recommended INN: List 67                                 WHO Drug Information, Vol. 26, No. 1, 2012


 naloxegolum
 naloxegol                 4,5α-epoxy-6α-[(3,6,9,12,15,18,21-heptaoxadocosan-1-yl)oxy]-
                           17-(prop-2-en-1-yl)morphinan-3,14-diol

 naloxégol                 4,5α-époxy-6α-[(3,6,9,12,15,18,21-heptaoxadocosan-1-yl)oxy]-
                           17-(prop-2-én-1-yl)morphinane-3,14-diol

 naloxegol                 4,5α-epoxi-6α-[(3,6,9,12,15,18,21-heptaoxadocosan-1-il)oxi]-
                           17-(prop-2-en-1-il)morfinan-3,14-diol

                           C34H53NO11

                                                              CH2
                                          H      N

                                         HO



                                             O            H
                                  HO             H O                    O
                                                                O
                           H 3C          O                      O
                                  O                  O                  O



 narnatumabum #
 narnatumab                immunoglobulin G1-kappa, anti-[Homo sapiens MST1R
                           (macrophage stimulating 1 receptor, macrophage stimulating protein
                           receptor, MSP receptor, c-met-related tyrosine kinase, protein-
                           tyrosine kinase 8, PTK8, RON, p185-Ron, CD136)], Homo sapiens
                           monoclonal antibody;
                           gamma1 heavy chain (1-452) [Homo sapiens VH (IGHV3-7*01
                           (95.90%) -(IGHD)-IGHJ6*01 T127>I (119)) [8.8.15] (1-122) -
                           IGHG1*03 (123-452)], (225-214')-disulfide with kappa light chain
                           (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) -
                           IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (231-231'':234-
                           234'')-bisdisulfide dimer

 narnatumab                immunoglobuline G1-kappa, anti-[Homo sapiens MST1R (récepteur
                           1 stimulant le macrophage, récepteur de la protéine stimulant le
                           macrophage, récepteur de la MSP, tyrosine kinase apparentée à
                           c-met, protéine-tyrosine kinase 8, PTK8, RON, p185-Ron, CD136)],
                           Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-452) [Homo sapiens VH (IGHV3-7*01
                           (95.90%) -(IGHD)-IGHJ6*01 T127>I (119)) [8.8.15] (1-122) -
                           IGHG1*03 (123-452)], (225-214')-disulfure avec la chaîne légère
                           kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) -
                           IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (231-
                           231'':234-234'')-bisdisulfure

 narnatumab                inmunoglobulina G1-kappa, anti-[Homo sapiens MST1R (receptor 1
                           estimulante el macrófago, receptor de la proteína estimulante el
                           macrófago, receptor de la MSP, tirosina kinasa relacionada con c-
                           met, proteína-tirosina kinase 8, PTK8, RON, p185-Ron, CD136)],
                           Homo sapiens anticuerpo monoclonal;
                           cadena pesada gamma1 (1-452) [Homo sapiens VH (IGHV3-7*01
                           (95.90%) -(IGHD)-IGHJ6*01 T127>I (119)) [8.8.15] (1-122) -
                           IGHG1*03 (123-452)], (225-214')-disulfuro con la cadena ligera
                           kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) -
                           IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (231-
                           231'':234-234'')-bisdisulfuro




74
WHO Drug Information, Vol. 26, No. 1, 2012                                                           Recommended INN: List 67




                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             EVQLVESGGG LVQPGGSLRL SCAASGFTFS                  SYLMTWVRQA       PGKGLEWVAN        50
                                             IKQDGSEKYY VDSVKGRFTI SRDNAKNSLN                  LQMNSLRAED       TAVYYCTRDG       100
                                             YSSGRHYGMD VWGQGTTVIV SSASTKGPSV                  FPLAPSSKST       SGGTAALGCL       150
                                             VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ                  SSGLYSLSSV       VTVPSSSLGT       200
                                             QTYICNVNHK PSNTKVDKRV EPKSCDKTHT                  CPPCPAPELL       GGPSVFLFPP       250
                                             KPKDTLMISR TPEVTCVVVD VSHEDPEVKF                  NWYVDGVEVH       NAKTKPREEQ       300
                                             YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN                  KALPAPIEKT       ISKAKGQPRE       350
                                             PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS                  DIAVEWESNG       QPENNYKTTP       400
                                             PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC                  SVMHEALHNH       YTQKSLSLSP       450
                                             GK                                                                                  452

                                             Light chain / Chaîne légère / Cadena ligera
                                             EIVLTQSPAT LSLSPGERAT LSCRASQSVS                  RYLAWYQQKP       GQAPRLLIYD 50
                                             ASNRATGIPA RFSGSGSGTD FTLTISSLEP                  EDFAVYYCQQ       RSNWPRTFGQ 100
                                             GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96 149-2105 266-326              372-430
                                                      22''-96'' 149''-205'' 266''-326'' 372''-430''
                                             Intra-L 23'-88'      134'-194'
                                                      23'''-88''' 134'''-194'''
                                             Inter-H-L 225-214' 225''-214'''
                                             Inter-H-H 231-231'' 234-234''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             302, 302''




 navarixinum
 navarixin                                   2-hydroxy-N,N-dimethyl-3-[(2-{[(1R)-1-(5-methylfuran-
                                             2-yl)propyl]amino}-3,4-dioxocyclobut-1-en-1-yl)amino]benzamide

 navarixine                                  2-hydroxy-N,N-diméthyl-3-[(2-{[(1R)-1-(5-méthylfuran-
                                             2-yl)propyl]amino}-3,4-dioxocyclobut-1-én-1-yl)amino]benzamide

 navarixina                                  2-hidroxi-N,N-dimetil-3-[(2-{[(1R)-1-(5-metilfuran-2-il)propil]amino}-
                                             3,4-dioxociclobut-1-en-1-il)amino]benzamida

                                             C21H23N3O5

                                                            H3C    O           O
                                                             H                                     CH3
                                             H3C       O                                           N
                                                                   N           N                       CH3
                                                                   H           H
                                                                                       OH      O



 nelociguatum
 nelociguat                                  methyl (4,6-diamino-2-{1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-
                                             b]pyridin-3-yl}pyrimidin-5-yl)carbamate

 nélociguat                                  (4,6-diamino-2-{1-[(2-fluorophényl)méthyl]-1H-pyrazolo[3,4-b]pyridin-
                                             3-yl}pyrimidin-5-yl)carbamate de méthyle

 nelociguat                                  (4,6-diamino-2-{1-[(2-fluorofenil)metil]-1H-pirazolo[3,4-b]piridin-
                                             3-il}pirimidin-5-il)carbamato de metilo




                                                                                                                                        75
Recommended INN: List 67                                  WHO Drug Information, Vol. 26, No. 1, 2012


                           C19H17FN8O2

                                                      NH2
                                                              H
                                                              N       O
                                                 N                        CH3
                                            N                     O
                           F                          N       NH2
                                        N


                                        N




 nintedanibum
 nintedanib                methyl (3Z)-3-[({4-[N-methyl-2-(4-methylpiperazin-
                           1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-2-oxo-
                           2,3-dihydro-1H-indole-6-carboxylate

 nintédanib                (3Z)-3-[({4-[N-méthyl-2-(4-méthylpipérazin-
                           1-yl)acétamido]phényl}amino)(phényl)méthylidène]-2-oxo-
                           2,3-dihydro-1H-indole-6-carboxylate de méthyle

 nintedanib                (3Z)-3-[({4-[N-metil-2-(4-metilpiperazin-
                           1-il)acetamido]fenil}amino)(fenil)metiliden]-2-oxo-2,3-dihidro-
                           1H-indol-6-carboxilato de metilo

                           C31H33N5O4

                                                          O
                                                HN
                                                              H
                                                              N                             CH3
                           H3C O                                                O       N
                                                                                    N
                                   O                                        N
                                                                            CH3



 nivocasanum
 nivocasan                 (5R)-N-[(2S,3S)-2-(fluoromethyl)-2-hydroxy-5-oxooxolan-3-yl]-
                           3-(isoquinolin-1-yl)-5-(propan-2-yl)-4,5-dihydro-1,2-oxazole-
                           5-carboxamide

 nivocasan                 (5R)-N-[(2S,3S)-2-(fluorométhyl)-2-hydroxy-5-oxooxolan-3-yl]-
                           3-(isoquinoléin-1-yl)-5-(propan-2-yl)-4,5-dihydro-1,2-oxazole-
                           5-carboxamide

 nivocasán                 (5R)-N-[(2S,3S)-2-(fluorometil)-2-hidroxi-5-oxooxolan-3-il]-
                           3-(isoquinolin-1-il)-5-(propan-2-il)-4,5-dihidro-1,2-oxazol-
                           5-carboxamida

                           C21H22FN3O5

                                                              O

                                                 O                O
                                                                      F
                               N                       N
                                                       H H OH
                                       N O           CH3
                                         H3C




76
WHO Drug Information, Vol. 26, No. 1, 2012                                                    Recommended INN: List 67


 oclacitinibum
 oclacitinib                                 N-methyl{trans-4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-
                                             4-yl)amino]cyclohexyl}methanesulfonamide

 oclacitinib                                 N-méthyl[trans-4-(méthyl-7H-pyrrolo[2,3-d]pyrimidin-
                                             4-ylamino)cyclohexyl]méthanesulfonamide

 oclacitinib                                 N-metil{trans-4-[metil(7H-pirrolo[2,3-d]pirimidin-
                                             4-il)amino]ciclohexil}metanosulfonamida

                                             C15H23N5O2S

                                                                             CH3
                                                                             N            N
                                                  O O
                                             H3C   S                             HN   N
                                                 N
                                                 H



 olcorolimusum
 olcorolimus                                 (3S,6S,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-
                                             9,27-dihydroxy-3-{(1R)-1-[(1S,3R,4R)-4-hydroxy-
                                             3-methoxycyclohexyl)propan-2-yl}-10,21-dimethoxy-
                                             6,8,12,14,20,26-hexamethyl-
                                             3,4,5,6,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34ª-
                                             icosahydro-11H-23,27-epoxypyrido[2,1-
                                             c][1,4]oxaazacyclohentriacontine-1,11,28,29(31H)-tetrone

 olcorolimus                                 (3S,6S,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-
                                             9,27-dihydroxy-3-{(1R)-1-[(1S,3R,4R)-4-hydroxy-
                                             3-méthoxycyclohexyl)propan-2-yl}-10,21-diméthoxy-
                                             6,8,12,14,20,26-hexaméthyl-
                                             3,4,5,6,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34ª-
                                             icosahydro-11H-23,27-époxypyrido[2,1-
                                             c][1,4]oxaazacyclohentriacontine-1,11,28,29(31H)-tétrone

 olcorolimús                                 (3S,6S,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-
                                             9,27-dihidroxi-3-{(1R)-1-[(1S,3R,4R)-4-hidroxi-
                                             3-metoxiciclohexil)propan-2-il}-10,21-dimetoxi-6,8,12,14,20,26-
                                             hexametil-3,4,5,6,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34ª-
                                             icosahidro-11H-23,27-epoxipirido[2,1-
                                             c][1,4]oxaazaciclohentriacontina-1,11,28,29(31H)-tetrona

                                             C51H81NO12

                                                         OH
                                                     H
                                                 H
                                             H3CO
                                                                   H
                                                                       CH3
                                                         O             H              H OH
                                                     H         H                               O
                                                               O
                                                                                  H
                                                     N         O         H3C H CH3 OCH3
                                                                              CH3
                                                               OH      H            H3C H
                                                                 O                                  H
                                                     O
                                                                                                   CH3
                                                         H                   H OCH3
                                                         H3C




                                                                                                                    77
Recommended INN: List 67                               WHO Drug Information, Vol. 26, No. 1, 2012




 ordopidinum
 ordopidine                1-ethyl-4-[2-fluoro-3-(methanesulfonyl)phenyl]piperidine

 ordopidine                1-éthyl-4-[2-fluoro-3-(méthylsulfonyl)phényl]pipéridine

 ordopidina                1-etil-4-[2-fluoro-3-(metanosulfonil)fenil]piperidina

                           C14H20FNO2S                                   871351-60-9



                           H3C
                                S
                               O O     F           N      CH3



 ozoralizumabum #
 ozoralizumab              immunoglobulin single chain VH-VH'-VH, trivalent bispecific anti-
                           [Homo sapiens TNF (tumor necrosis factor, TNF superfamily
                           member 2, TNFSF2, TNFA, TNF-alpha)] VH and anti-[Homo sapiens
                           ALB (albumin, human serum albumin, HAS)] VH', humanized Lama
                           glama monoclonal antibody;
                           scVH-VH'-VH (1-363) [humanized VH (Homo sapiens IGHV3-74*01
                           (88.80%) -(IGHD)-IGHJ1*01 W118>R (105)) [8.8.8] (1-115) - 9-mer
                           linker (tetraglycyl-seryl-triglycyl-seryl) (116-124) -humanized VH'
                           (Homo sapiens IGHV3-23*04 (89.60%) -(IGHD)-IGHJ1*01 W118>S
                           (229), G119>S (230) [8.8.8] (125-239) -9-mer linker (tetraglycyl-
                           seryl-triglycyl-seryl) (240-248) -humanized VH (Homo sapiens
                           IGHV3-74*01 (88.80%) -(IGHD)-IGHJ1*01 W118>R (353)(249-363)

 ozoralizumab              immunoglobuline single chain VH-VH'-VH, trivalente bispécifique
                           anti-[Homo sapiens TNF (facteur de nécrose tumorale, membre 2 de
                           la superfamille du TNF, TNFSF2, TNFA, TNF-alpha)] VH et anti-
                           [Homo sapiens ALB (albumine, sérum albumine humaine, SAH)]
                           VH', anticorps monoclonal de Lama glama humanisé;
                           scVH-VH'-VH (1-363) [VH humanisé (Homo sapiens IGHV3-74*01
                           (88.80%) -(IGHD)-IGHJ1*01 W118>R (105)) [8.8.8] (1-115) -9-mer
                           linker (tétraglycyl-séryl-triglycyl-séryl) (116-124) -VH' humanisé
                           (Homo sapiens IGHV3-23*04 (89.60%) -(IGHD)-IGHJ1*01 W118>S
                           (229), G119>S (230) [8.8.8] (125-239) -9-mer linker (tétraglycyl-
                           séryl-triglycyl-séryl) (240-248) -VH humanisé (Homo sapiens IGHV3-
                           74*01 (88.80%) -(IGHD)-IGHJ1*01 W118>R (353)(249-363)

 ozoralizumab              inmunoglobulina de cadena sencilla VH-VH'-VH, trivalente
                           biespecífica anti-[TNF de Homo sapiens (factor de necrosis tumoral,
                           miembro 2 de la superfamilia del TNF, TNFSF2, TNFA, TNF-alpha)]
                           VH y anti-[Homo sapiens ALB (albumina, albumina sérica humana
                           SAH)] VH', anticuerpo monoclonal de Lama glama humanizado;
                           scVH-VH'-VH (1-363) [VH humanizado (Homo sapiens IGHV3-74*01
                           (88.80%) -(IGHD)-IGHJ1*01 W118>R (105)) [8.8.8] (1-115) -
                           conector nonámero (tetraglicil-seril-triglicil-seril) (116-124) -VH'
                           humanizado (Homo sapiens IGHV3-23*04 (89.60%) -(IGHD)-
                           IGHJ1*01 W118>S (229), G119>S (230) [8.8.8] (125-239) -
                           espaciador nonámero (tetraglicil-seril-triglicil-seril) (240-248) -VH
                           humanizado (Homo sapiens IGHV3-74*01 (88.80%) -(IGHD)-
                           IGHJ1*01 W118>R (353)(249-363)




78
WHO Drug Information, Vol. 26, No. 1, 2012                                                           Recommended INN: List 67




                                             scVH-VH'-VH chain / Chaîne scVH-VH'-VH / Cadena scVH-VH'-VH
                                             EVQLVESGGG LVQPGGSLRL SCAASGFTFS DYWMYWVRQA PGKGLEWVSE                               50
                                             INTNGLITKY PDSVKGRFTI SRDNAKNTLY LQMNSLRPED TAVYYCARSP                              100
                                             SGFNRGQGTL VTVSSGGGGS GGGSEVQLVE SGGGLVQPGN SLRLSCAASG                              150
                                             FTFSSFGMSW VRQAPGKGLE WVSSISGSGS DTLYADSVKG RFTISRDNAK                              200
                                             TTLYLQMNSL RPEDTAVYYC TIGGSLSRSS QGTLVTVSSG GGGSGGGSEV                              250
                                             QLVESGGGLV QPGGSLRLSC AASGFTFSDY WMYWVRQAPG KGLEWVSEIN                              300
                                             TNGLITKYPD SVKGRFTISR DNAKNTLYLQ MNSLRPEDTA VYYCARSPSG                              350
                                             FNRGQGTLVT VSS                                                                      363

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-chain 22-96 146-220 270-34




 pateclizumabum #
 pateclizumab                                immunoglobulin G1-kappa, anti-[Homo sapiens LTA (lymphotoxin
                                             alpha, TNFSF1, tumor necrosis factor superfamily member 1, LT)],
                                             humanized monoclonal antibody;
                                             gamma1 heavy chain (1-447) [humanized VH (Homo sapiens
                                             IGHV3-74*01 (76.50%) -(IGHD)-IGHJ5*01) [8.9.11] (1-118) -Homo
                                             sapiens IGHG1*03 CH1 R120>K (215), CH3 K130>del (119-447)],
                                             (221-214')-disulfide with kappa light chain (1'-214') [humanized
                                             V-KAPPA (Homo sapiens IGKV1-39*01 (88.40%) -IGKJ1*01) [6.3.9]
                                             (1'-107') -Homo sapiens IGKC*01 (108'-214')]; (227-227":230-230")-
                                             bisdisulfide dimer

 patéclizumab                                immunoglobuline G1-kappa, anti-[Homo sapiens LTA (lymphotoxine
                                             alpha, TNFSF1, membre 1 de la superfamille du facteur de nécrose
                                             tumorale, LT)], anticorps monoclonal humanisé;
                                             chaîne lourde gamma1 (1-447) [VH humanisé (Homo sapiens
                                             IGHV3-74*01 (76.50%) -(IGHD)-IGHJ5*01) [8.9.11] (1-118) -Homo
                                             sapiens IGHG1*03 CH1 R120>K (215), CH3 K130>del (119-447)],
                                             (221-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA
                                             humanisé (Homo sapiens IGKV1-39*01 (88.40%) -IGKJ1*01) [6.3.9]
                                             (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (227-
                                             227":230-230")-bisdisulfure

 pateclizumab                                inmunoglobulina G1-kappa, anti-[LTA de Homo sapiens (linfotoxina
                                             alfa, TNFSF1, miembro 1 de la superfamilia del factor de necrosis
                                             tumoral, LT)], anticuerpo monoclonal humanizado;
                                             cadena pesada gamma1 (1-447) [VH humanizada (Homo sapiens
                                             IGHV3-74*01 (76.50%) -(IGHD)-IGHJ5*01) [8.9.11] (1-118) -Homo
                                             sapiens IGHG1*03 CH1 R120>K (215), CH3 K130>del (119-447)],
                                             (221-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA
                                             humanizada (Homo sapiens IGKV1-39*01 (88.40%) -IGKJ1*01)
                                             [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (227-
                                             227":230-230")-bisdisulfuro




                                                                                                                                         79
Recommended INN: List 67                                    WHO Drug Information, Vol. 26, No. 1, 2012




                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVQPGGSLRL SCAASGYTFT                  SYVIHWVRQA       PGKGLEWVGY        50
                           NNPYNAGTNY NEKFKGRFTI SSDKSKNTAY                  LQMNSLRAED       TAVYYCSRPT       100
                           MLPWFAYWGQ GTLVTVSSAS TKGPSVFPLA                  PSSKSTSGGT       AALGCLVKDY       150
                           FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSSLGTQTYI       200
                           CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC                  PAPELLGGPS       VFLFPPKPKD       250
                           TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                  DGVEVHNAKT       KPREEQYNST       300
                           YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                  APIEKTISKA       KGQPREPQVY       350
                           TLPPSREEMT KNQVSLTCLV KGFYPSDIAV                  EWESNGQPEN       NYKTTPPVLD       400
                           SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                  EALHNHYTQK       SLSLSPG          447

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCRASQAVS                  SAVAWYQQKP       GKAPKLLIYS 50
                           ASHRYTGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQE       SYSTPWTFGQ 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 145-201              262-322  368-426
                                    22''-96'' 145''-201'' 262''-322'' 368''-426''
                           Intra-L 23'-88'      134'-194'
                                    23'''-88''' 134'''-194'''
                           Inter-H-L 221-214' 221''-214'''
                           Inter-H-H 227-227'' 230-230''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           298, 298''



 pegadricasum #
 pegadricase               pegylated Urate Oxidase from Candida utilis,
                           [198-threonine(S>T)]uricase (EC 1.7.3.3, urate oxidase) Pichia
                           jadinii (Yeast) (Candida utilis) tetramer, 6-amino group of an average
                           of 3 lysine residues, mostly in position 16, 19, and 85 of each
                           monomer, are amidified with α-(3-carboxypropanoyl)-
                           ω-methoxypoly(oxyethylene)

 pégadricase               urate oxidase de Candida utilis pégylée,
                           [198-thréonine(S>T)]uricase (EC 1.7.3.3, urate oxydase) Pichia
                           jadinii (levure) (Candida utilis), tétramère, la fonction amine en 6 de
                           certaines lysines, en moyenne 3, principalement en positions 16, 19,
                           et 85 de chaque monomère, sont amidifiées par le
                           α-(3-carboxypropanoyl)-ω-méthoxypoly(oxyéthylène)

 pegadricasa               urato oxidasa de Candida utilis pegilada,
                           [198-treonina(S>T)]uricasa (EC 1.7.3.3, urato oxidasa) Pichia jadinii
                           (levadura) (Candida utilis), tetrámero, la función amina en 6 de
                           ciertas lisinas, 3 por término medio, principalmente en las posiciones
                           16, 19, y 85 de cada monómero, está amidificada con
                           α-(3-carboxipropanoil)-ω-metoxipoli(oxietileno)

                           Monomer / Monomère / Monómero
                           MSTTLSSSTY GKDNVKFLKV KKDPQNPKKQ                       EVMEATVTCL      LEGGFDTSYT         50
                           EADNSSIVPT DTVKNTILVL AKTTEIWPIE                       RFAAKLATHF      VEKYSHVSGV        100
                           SVKIVQDRWV KYAVDGKPHD HSFIHEGGEK                       RITDLYYKRS      GDYKLSSAIK        150
                           DLTVLKSTGS MFYGYNKCDF TTLQPTTDRI                       LSTDVDATWV      WDNKKIGTVY        200
                           DIAKAADKGI FDNVYNQARE ITLTTFALEN                       SPSVQATMFN      MATQILEKAC        250
                           SVYSVSYALP NKHYFLIDLK WKGLENDNEL                       FYPSPHPNGL      IKCTVVRKEK        300
                           TKL                                                                                      303

                           Modified residues / Résidus modifiés / Residuos modificados
                                                                                              O
                                        K
                                    16, 19, 85         H3 C                   O
                                                            O                                     NH
                              main pegylation sites                           n
                            principaux sites pégylés                                  O
                            principios sitios pegilado                            H

                                                                              N
                                                                              H
                                                                                          O



80
WHO Drug Information, Vol. 26, No. 1, 2012                                                                  Recommended INN: List 67




 peginterferonum lambda-1a #
 peginterferon lambda-1a                     pegylated interferon lambda-1; pegylated interleukin 29;
                                             N-{3-[α-methylpoly(oxyethylene)oxy]propyl}-L-methionyl{[171-
                                             serine]human interleukin-29 (IFN-λ-1)-(7-181)-peptide}

 péginterféron lambda-1a                     interféron lambda-1 pégylé; interleukine-29 pégylée;
                                             N-{3-[α-méthylpoly(oxyéthylène)oxy]propyl}-L-méthionyl{[171-sérine]
                                             interleukine-29 humaine (IFN-λ-1)-(7-181)-peptide}

 peginterferón lambda-1a                     interferón lambda-1 pegilado; interleukina-29 pegilada;
                                             N-{3-[α-metilpoli(oxietileno)oxi]propil}-L-metionil{[171-serina]
                                             interleukina-29 humana (IFN-λ-1)-(7-181)-péptido}

                                             C875H1408N254O251S5 (C2H4O)n

                                                  MKPTT          TGKGCHIGRF         KSLSPQELAS           FKKARDALEE SLKLKNWSCS 50
                                             SPVFPGNWDL          RLLQVRERPV         ALEAELALTL           KVLEAAAGPA LEDVLDQPLH 100
                                             TLHHILSQLQ          ACIQPQPTAG         PRPRGRLHHW           LHRLQEAPKK ESAGCLEASV 150
                                             TFNLFRLLTR          DLKYVADGNL         SLRTSTHPES           T                     181

                                             Modified residue / Résidu modifié / Residuo modificado
                                                                                                           CH3
                                                                                                       S
                                                                                                   H
                                                  M
                                                  1               O
                                                           H3C                O              N
                                                                             n               H
                                                                                                     O

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             15-112 49-145




 pegnivacoginum
 pegnivacogin                                a ribonucleic acid aptamer which binds Factor XIa;
                                             ester of 2'-O-methyl-5'-O-phosphonoguanylyl-(3'→5')-2'-O-
                                             methyluridylyl-(3' →5')-2'-O-methylguanylyl-(3'→5')-2'-O-
                                             methylguanylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-deoxy-2'-
                                             fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-O-
                                             methyladenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-O-
                                             methyladenylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-
                                             2'-fluorocytidylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-deoxy-2'-
                                             fluorocytidylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-deoxy-2'-
                                             fluorouridylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-
                                             methyladenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-O-
                                             methylguanylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-O-
                                             methyluridylyl-(3'→5')-guanylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-
                                             2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-
                                             2'-O-methylcytidylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-
                                             methyladenylyl-(3'→5')-2'-O-methylcytidylyl-(3'→3')-thimidine with
                                             6-[(2,6-bis{N-[ω-methoxypoly(oxyethylene)carbonyl]}-
                                             DL-lysyl)amino]hexan-1-ol




                                                                                                                                               81
Recommended INN: List 67                               WHO Drug Information, Vol. 26, No. 1, 2012


 pégnivacogin              acide ribonucleique aptamère se liant au Factor XIa;
                           ester de 2'-O-méthyl-5'-O-phosphonoguanylyl-(3'→5')-2'-O-
                           méthyluridylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-
                           méthylguanylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-déoxy-2'-
                           fluorocytidylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-O-
                           méthyladénylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-O-
                           méthyladénylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-déoxy-
                           2'-fluorocytidylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-déoxy-2'-
                           fluorocytidylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-déoxy-2'-
                           fluorouridylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-O-
                           méthyladénylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-O-
                           méthylguanylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-O-
                           méthyluridylyl-(3'→5')-guanylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-
                           2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-
                           2'-O-méthylcytidylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O-
                           méthyladénylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→3')-thimidine avec
                           6-[(2,6-bis{N-[ω-méthoxypoly(oxyéthylène)carbonyl]}-
                           DL-lysyl)amino]hexan-1-ol

 pegnivacogina             aptámero de ácido ribomucléico que se une a Factor XIa;
                           éster of 2'-O-metil-5'-O-fosfonoguanilil-(3'→5')-2'-O-metiluridilil-
                           (3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-
                           metiladenilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-
                           fluorouridilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-
                           fluorouridilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-
                           fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-O-
                           metilguanilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-O-
                           metilguanilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-O-
                           metiladenilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-
                           fluorouridilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-desoxi-2'-
                           fluorocitidilil-(3'→5')-2'-O-metiluridilil-(3'→5')-guanilil-(3'→5')-2'-O-
                           metilcitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-
                           fluorouridilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-
                           2'-O-metiladenilil-(3'→5')-2'-O-metilcitidilil-(3'→3')-timidina con
                           6-[(2,6-bis{N-[ω-metoxipoli(oxietileno)carbonil]}-DL-lisil)amino]hexan-
                           1-ol

                           C327H422F11N114O213P31 (C2H4O)n

                           (3'-5')-R-pmG-mU-mG-mG-mA-dflC-dflU-mA-dflU-mA-dflC-dflC-mG-
                           dflC-mG-dflU-mA-mA-dflU-mG-dflC-mU-G-mC-dflC-dflU-mC-mC-mA-mC3'-3'dT
                           Legend:
                           dfl = 2'-deoxy-2'-fluoro ; m = 2'-O-methyl ; p (as prefix) = 5'-phosphate

                            R- =                                  O
                                                                          O
                                                              N       O       CH3
                            x+y=n                             H           y
                                              O
                                                  H       H
                                   O                      N                CH2
                            H3C           O     N
                                              x H
                                                      O



 pimasertibum
 pimasertib                N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-
                           4-iodophenyl)amino]pyridine-4-carboxamide

 pimasertib                N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-
                           4-iodophényl)amino]pyridine-4-carboxamide

 pimasertib                N-[(2S)-2,3-dihidroxipropil]-3-[(2-fluoro-4-iodofenil)amino]piridina-
                           4-carboxamida



82
WHO Drug Information, Vol. 26, No. 1, 2012                                                     Recommended INN: List 67


                                             C15H15FIN3O3

                                                                  N       F         I


                                                                          N
                                                                          H
                                             HO               N       O
                                                              H
                                                     H OH



 recoflavonum
 recoflavone                                 {[2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxo-4H-chromen-
                                             7-yl]oxy}acetic acid

 récoflavone                                 acide {[2-(3,4-diméthoxyphényl)-5-méthoxy-4-oxo-4H-chromen-
                                             7-yl]oxy}acétique

 recoflavona                                 ácido {[2-(3,4-dimetoxifenil)-5-metoxi-4-oxo-4H-cromen-
                                             7-il]oxi}acético

                                             C20H18O8

                                                                               OCH3
                                                                                        OCH3

                                             HO2C         O               O




                                                                  OCH3 O



 rucaparibum
 rucaparib                                   8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-
                                             6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one

 rucaparib                                   8-fluoro-2-{4-[(méthylamino)méthyl]phényl}-1,3,4,5-tétrahydro-
                                             6H-pyrrolo[4,3,2-ef][2]benzazépin-6-one

 rucaparib                                   8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-
                                             6H-pirrolo[4,3,2-ef][2]benzazepin-6-ona

                                             C19H18FN3O

                                                              H
                                             F                N

                                                                              HN   CH3

                                                 O
                                                      N
                                                      H



 safotibantum
 safotibant                                  N-{[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl}-2-{2-[(4-methoxy-
                                             2,6-dimethylbenzenesulfonyl)(methyl)amino]ethoxy}-
                                             N-methylacetamide

 safotibant                                  N-{[4-(4,5-dihydro-1H-imidazol-2-yl)phényl]méthyl}-2-{2-[(4-méthoxy-
                                             2,6-diméthylbenzènesulfonyl)(méthyl)amino]éthoxy}-
                                             N-méthylacétamide


                                                                                                                     83
Recommended INN: List 67                                WHO Drug Information, Vol. 26, No. 1, 2012




 safotibant                N-{[4-(4,5-dihidro-1H-imidazol-2-il)fenil]metil}-2-{2-[(4-metoxi-
                           2,6-dimetilbencenosulfonil)(metil)amino]etoxi}-N-metilacetamido

                           C25H34N4O5S

                                                                                              N
                           H3CO             CH3
                                                  CH3                       CH3                   N
                                                                                                  H
                                                  N                         N
                                          S                  O
                                     CH3 O O                           O



 selepressinum
 selepressin               vasopressin type 1a (V1a) receptor agonist;
                           [2-L-phenylalanine,3-L-isoleucine,4-(6-oxo-L-lysine),8-[5-N-(propan-
                           2-yl)-L-ornithine]]human vasopressin

 sélépressine              agoniste du récepteur de la vasopressine type 1a (V1a);
                           [2-L-phénylalanine,3-L-isoleucine,4-(6-oxo-L-lysine),8-[5-N-(propan-
                           2-yl)-L-ornithine]]vasopressine humaine

 selepresina               agonista del receptor de la vasopresina tipo 1ª (V1a);
                           [2-L-fenillalanina,3-L-isoleucina,4-(6-oxo-L-lisina),8-[5-N-(propan-
                           2-yl)-L-ornitina]]vasopresina humana

                           C46H73N13O11S2

                                                                            CH3
                                   H2 N                          H3C
                                                                           HN
                                     O                H                                   H

                           H Cys    Phe   Ile   N            Asn   Cys          Pro   N           Gly NH2
                                                H                                     H
                                                        O                                 O



 sepantronii bromidum
 sepantronium bromide      1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-[(pyrazin-2-yl)methyl]-
                           4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide

 bromure de sépantronium   bromure de 1-(2-méthoxyéthyl)-2-méthyl-4,9-dioxo-3-[(pyrazin-
                           2-yl)méthyl]-4,9-dihydro-1H-naphto[2,3-d]imidazolium

 bromuro de sepantronio    bromuro de 2-metil-1-(2-metoxietil)-4,9-dioxo-3-[(pirazin-2-il)metil]-
                           4,9-dihidro-1H-nafto[2,3-d]imidazolio

                           C20H19BrN4O3

                                    O
                                                    O CH3
                                          N
                                                  CH3       Br
                                          N
                                                        N
                                    O
                                                  N




84
WHO Drug Information, Vol. 26, No. 1, 2012                                                            Recommended INN: List 67


 serelaxinum
 serelaxin                                   human relaxin 2 (relaxin H2)

 sérélaxine                                  rélaxine 2 humaine (rélaxine H2)

 serelaxina                                  relaxina 2 humana (relaxina H2)

                                             C256H408N74O74S8

                                             B chain / Chaîne B / Cadena B
                                             DSWMEEVIKL CGRELVRAQI AICGMSTWS                   29

                                             A chain / Chaîne A / Cadena A
                                             QLYSALANKC CHVGCTKRSL ARFC                        24'

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             10'-15' 11-11' 23-24'

                                             Modified residue / Résidu modifié / Residuo modificado

                                                      Q                             H
                                                      1'                            CO2H
                                              L-pyroglutamic acid               N
                                                                        O       H




 seridopidinum
 seridopidine                                1-ethyl-4-[3-fluoro-5-(methanesulfonyl)phenyl]piperidine

 séridopidine                                1-éthyl-4-[3-fluoro-5-(méthylsulfonyl)phényl]pipéridine

 seridopidina                                1-etil-4-[3-fluoro-5-(metanosulfonil)fenil]piperidina

                                             C14H20FNO2S

                                                            F



                                             H3C
                                                  S
                                                 O O                        N       CH3



 simeprevirum
 simeprevir                                  (2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropanesulfonyl)-
                                             2-({7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-
                                             4-yl}oxy)-5-methyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-
                                             tetradecahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotetradecine-
                                             12a(1H)-carboxamide

 siméprévir                                  (2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropanesulfonyl)-
                                             2-({7-méthoxy-8-méthyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinoléin-
                                             4-yl}oxy)-5-méthyl-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-
                                             tétradécahydrocyclopenta[c]cyclopropa[g][1,6]diazacyclotétradécine-
                                             12a(1H)-carboxamide

 simeprevir                                  (2R,3aR,10Z,11aS,12aR,14aR)-N-(ciclopropanosulfonil)-
                                             2-({7-metoxi-8-metil-2-[4-(propan-2-il)-1,3-tiazol-2-il]quinolin-4-il}oxi)-
                                             5-metil-4,14-dioxo-2,3,3a,4,5,6,7,8,9,11a,12,13,14,14a-
                                             tetradecahidrociclopenta[c]ciclopropa[g][1,6]diazaciclotetradecina-
                                             12a(1H)-carboxamida




                                                                                                                                          85
Recommended INN: List 67                                           WHO Drug Information, Vol. 26, No. 1, 2012


                           C38H47N5O7S2

                                      O
                                                                    OCH3
                                  O       S
                                                                           CH3
                              O           NH
                                               O
                                                   H
                                                                           N
                                          N                    H
                                          H                                        N       CH3
                              H                                O
                                               H
                                                                               S           CH3

                                               N       O
                                               CH3



 siponimodum
 siponimod                 1-({4-[(1E)-1-({[4-cyclohexyl-
                           3-(trifluoromethyl)phenyl]methoxy}imino)ethyl]-
                           2-ethylphenyl}methyl)azetidine-3-carboxylic acid

 siponimod                 acide 1-({4-[(1E)-1-({[4-cyclohexyl-
                           3-(trifluorométhyl)phényl]méthoxy}imino)éthyl]-
                           2-éthylphényl}méthyl)azétidine-3-carboxylique

 siponimod                 ácido 1-({4-[(1E)-1-({[4-ciclohexil-
                           3-(trifluorometil)fenil]metoxi}imino)etil]-2-etilfenil}metil)azetidina-
                           3-carboxílico

                           C29H35F3N2O3

                                                                                       N
                                                               N                             CO2H
                                                           O
                                                                    CH3            CH3

                                               CF3



 sirukumabum #
 sirukumab                 immunoglobulin G1-kappa, anti-[Homo sapiens IL6 (interleukin 6,
                           IL-6)], Homo sapiens monoclonal antibody;
                           gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV3-7*01
                           (87.80%) -(IGHD)-IGHJ6*01) [8.8.12] (1-119) -IGHG1*01 (120-449)],
                           (222-213')-disulfide with kappa light chain (1'-213') [Homo sapiens
                           V-KAPPA (IGKV3-11*01 (87.40%) -IGKJ4*01) [5.3.9] (1'-107') -
                           IGKC*01 (107'-213')]; (228-231'':228-231'')-bisdisulfide dimer

 sirukumab                 immunoglobuline G1-kappa, anti-[Homo sapiens IL6 (interleukine 6,
                           IL-6)], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV3-7*01
                           (87.80%) -(IGHD)-IGHJ6*01) [8.8.12] (1-119) -IGHG1*01 (120-449)],
                           (222-213')-disulfure avec la chaîne légère kappa (1'-213') [Homo
                           sapiens V-KAPPA (IGKV3-11*01 (87.40%) -IGKJ4*01) [5.3.9] (1'-
                           107') -IGKC*01 (107'-213')]; dimère (228-228'':231-231'')-bisdisulfure




86
WHO Drug Information, Vol. 26, No. 1, 2012                                                           Recommended INN: List 67




 sirukumab                                   inmunoglobulina G1-kappa, anti-[IL6 de Homo sapiens (interleukina
                                             6, IL-6)], anticuerpo monoclonal de Homo sapiens;
                                             cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV3-7*01
                                             (87.80%) -(IGHD)-IGHJ6*01) [8.8.12] (1-119) -IGHG1*01 (120-449)],
                                             (222-213')-disulfuro con la cadena ligera kappa (1'-213') [Homo
                                             sapiens V-KAPPA (IGKV3-11*01 (87.40%) -IGKJ4*01) [5.3.9] (1'-
                                             107') -IGKC*01 (107'-213')]; dímero (228-228'':231-231'')-bisdisulfuro

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             EVQLVESGGG LVQPGGSLRL SCAASGFTFS                  PFAMSWVRQA       PGKGLEWVAK        50
                                             ISPGGSWTYY SDTVTGRFTI SRDNAKNSLY                  LQMNSLRAED       TAVYYCARQL       100
                                             WGYYALDIWG QGTTVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD       150
                                             YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY       200
                                             ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK       250
                                             DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS       300
                                             TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV       350
                                             YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL       400
                                             DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK        449

                                             Light chain / Chaîne légère / Cadena ligera
                                             EIVLTQSPAT LSLSPGERAT LSCSASISVS                  YMYWYQQKPG       QAPRLLIYDM 50
                                             SNLASGIPAR FSGSGSGTDF TLTISSLEPE                  DFAVYYCMQW       SGYPYTFGGG 100
                                             TKVEIKRTVA APSVFIFPPS DEQLKSGTAS                  VVCLLNNFYP       REAKVQWKVD 150
                                             NALQSGNSQE SVTEQDSKDS TYSLSSTLTL                  SKADYEKHKV       YACEVTHQGL 200
                                             SSPVTKSFNR GEC                                                                213

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96        146-202       263-323  369-427
                                                       22''-96'' 146''-202'' 263''-323'' 369''-427''
                                             Intra-L 23'-87'      133'-193'
                                                      23'''-87''' 133'''-193'''
                                             Inter-H-L 222-213' 222''-213'''
                                             Inter-H-H 228-228'' 231-231''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             299, 299''




 solithromycinum
 solithromycin                               (3aR,4R,7S,9R,10R,11R,13R,15R,15aR)-1-{4-[4-(3-aminophenyl)-
                                             1H-1,2,3-triazol-1-yl]butyl}-4-ethyl-7-fluoro-11-methoxy-
                                             3ª,7,9,11,13,15-hexamethyl-10-{[trideoxy-(dimethylamino)-
                                             β-D-hexopyranosyl]oxy}octahydro-2H-oxacyclotetradecino[4,3-
                                             b][1,3]oxazole-2,6,8,14(1H,7H,9H)-tetraone

 solithromycine                              (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-1-{4-[4-(3-aminophényl)-
                                             1H-1,2,3-triazol-1-yl]butyl}-4-éthyl-7-fluoro-11-méthoxy-
                                             3a,7,9,11,13,15-hexaméthyl-10-{[3,4,6-tridéoxy-3-(diméthylamino)-
                                             β-D-xylo-hexopyranosyl]oxy}octahydro-2H-oxacyclotétradécino[4,3-
                                             d]oxazole-2,6,8,14(1H,7H,9H)-tétrone

 solitromicina                               (3aR,4R,7S,9R,10R,11R,13R,15R,15aR)-1-{4-[4-(3-aminofenil)-
                                             1H-1,2,3-triazol-1-il]butil}-4-etil-7-fluoro-3ª,7,9,11,13,15-hexametil-
                                             11-metoxi-10-{[tridesoxi-(dimetilamino)-
                                             β-D-hexopiranosil]oxi}octahidro-2H-oxaciclotetradecino[4,3-
                                             b][1,3]oxazol-2,6,8,14(1H,7H,9H)-tetraona




                                                                                                                                         87
Recommended INN: List 67                                       WHO Drug Information, Vol. 26, No. 1, 2012




                           C43H65FN6O10                                                            760981-83-7



                                                                                  O
                           H2N                                            H                   CH3
                                                       N        H3C
                                              N                                                H
                                                   N
                                                                                                CH3
                                                           H3CO                   H
                                             H3C                                                  O
                                                                                      N
                                                        O H3C
                                                                                  H
                                                            O                        O                   O
                                                                    H             CH3 H
                                                                                                   CH3
                                        H3 C N             OH       O                          O
                                                   CH3                        F       CH3



 spriferminum #
 sprifermin                L-methionyl[human           fibroblast growth factor 18 (FGF-18, zFGF5)-
                           (1-169)-peptide

 sprifermine               L-méthionyl[facteur
                                             18 de croissance du fibroblaste humain (FGF-18,
                           zFGF5)-(1-169)-peptide]

 esprifermina              L-metionil[factor 18 de crecimiento de fibroblastos humanos (FGF-
                           18, zFGF5)-(1-169)-péptido]

                           C876H1396N258O256S6

                                                                                                                     M
                           EENVDFRIHV        ENQTRARDDV         SRKQLRLYQL                    YSRTSGKHIQ     VLGRRISARG   50
                           EDGDKYAQLL        VETDTFGSQV         RIKGKETEFY                    LCMNRKGKLV     GKPDGTSKEC   100
                           VFIEKVLENN        YTALMSAKYS         GWYVGFTKKG                    RPRKGPKTRE     NQQDVHFMKR   150
                           YPKGQPELQK        PFKYTTVTK                                                                    169

                           Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro
                           82-100




 suvorexantum
 suvorexant                [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-
                           methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone

 suvorexant                [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-méthyl-1,4-diazépan-1-yl][5-
                           méthyl-2-(2H-1,2,3-triazol-2-yl)phényl]méthanone

 suvorexant                [(7R)-4-(5-cloro-1,3-benzoxazol-2-il)-7-metil-1,4-diazepan-1-il][5-
                           metil-2-(2H-1,2,3-triazol-2-il)fenil]metanona

                           C23H23ClN6O2

                                                                    CH3
                                             O
                                                                     H
                                                    N
                                                                N         O
                           Cl                N                                    N
                                                                                  N
                                                                                          N

                                                        H3 C




88
WHO Drug Information, Vol. 26, No. 1, 2012                                                           Recommended INN: List 67


 tabalumabum #
 tabalumab                                   immunoglobulin G4-kappa, anti-[Homo sapiens TNFSF13B (tumor
                                             necrosis factor superfamily member 13B, BAFF, THANK, TALL-1,
                                             TALL1, BLYS, BLyS, B cell activating factor, B lymphocyte
                                             stimulator, CD257)], Homo sapiens monoclonal antibody;
                                             gamma4 heavy chain (1-450) [Homo sapiens VH (IGHV4-34*01
                                             (100.00%) -(IGHD)-IGHJ4*01) [8.7.17] (1-123) -IGHG4*01 hinge
                                             S10>P (231) (124-450)], (137-214')-disulfide with kappa light chain
                                             (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (97.90%) -
                                             IGKJ1*01) [6.3.9] (1'-107') -IGKC*05 (108'-214')]; (229-229'':232-
                                             232'')-bisdisulfide dimer

 tabalumab                                   immunoglobuline G4-kappa, anti-[Homo sapiens TNFSF13B
                                             (membre 13B de la superfamille du facteur de nécrose tumorale,
                                             BAFF, THANK, TALL-1, TALL1, BLYS, BLyS, facteur d'activation
                                             des cellules B, stimulateur des lymphocytes B, CD257)], Homo
                                             sapiens anticorps monoclonal;
                                             chaîne lourde gamma4 (1-450) [Homo sapiens VH (IGHV4-34*01
                                             (100.00%) -(IGHD)-IGHJ4*01) [8.7.17] (1-123) -IGHG4*01 charnière
                                             S10>P (231) (124-450)], (137-214')-disulfure avec la chaîne légère
                                             kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (97.90%) -
                                             IGKJ1*01) [6.3.9] (1'-107') -IGKC*05 (108'-214')]; dimère (229-
                                             229'':232-232'')-bisdisulfure

 tabalumab                                   inmunoglobulina G4-kappa, anti-[TNFSF13B de Homo sapiens
                                             (miembro 13B de la superfamilia del factor de necrosis tumoral,
                                             BAFF, THANK, TALL-1, TALL1, BLYS, BLyS, factor de activación de
                                             células B, estimulante de linfocitos B, CD257)], Homo sapiens
                                             anticuerpo monoclonal;
                                             cadena pesada gamma4 (1-450) [VH de Homo sapiens (IGHV4-
                                             34*01 (100.00%) -(IGHD)-IGHJ4*01) [8.7.17] (1-123) -IGHG4*01
                                             bisagra S10>P (231) (124-450)], (137-214')-disulfuro con la cadena
                                             ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01
                                             (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*05 (108'-214')]; dímero
                                             (229-229'':232-232'')-bisdisulfuro

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLQQWGAG LLKPSETLSL TCAVYGGSFS                  GYYWSWIRQP       PGKGLEWIGE        50
                                             INHSGSTNYN PSLKSRVTIS VDTSKNQFSL                  KLSSVTAADT       AVYYCARGYY       100
                                             DILTGYYYYF DYWGQGTLVT VSSASTKGPS                  VFPLAPCSRS       TSESTAALGC       150
                                             LVKDYFPEPV TVSWNSGALT SGVHTFPAVL                  QSSGLYSLSS       VVTVPSSSLG       200
                                             TKTYTCNVDH KPSNTKVDKR VESKYGPPCP                  PCPAPEFLGG       PSVFLFPPKP       250
                                             KDTLMISRTP EVTCVVVDVS QEDPEVQFNW                  YVDGVEVHNA       KTKPREEQFN       300
                                             STYRVVSVLT VLHQDWLNGK EYKCKVSNKG                  LPSSIEKTIS       KAKGQPREPQ       350
                                             VYTLPPSQEE MTKNQVSLTC LVKGFYPSDI                  AVEWESNGQP       ENNYKTTPPV       400
                                             LDSDGSFFLY SRLTVDKSRW QEGNVFSCSV                  MHEALHNHYT       QKSLSLSLGK       450

                                             Light chain / Chaîne légère / Cadena ligera
                                             EIVLTQSPAT LSLSPGERAT LSCRASQSVS                  RYLAWYQQKP       GQAPRLLIYD 50
                                             ASNRATGIPA RFSGSGSGTD STLTISSLEP                  EDFAVYYCQQ       RSNWPRTFGQ 100
                                             GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSNTLT                  LSKADYEKHK       VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-95        150-206       264-324  370-428
                                                       22''-95'' 150''-206'' 264''-324'' 370''-428''
                                             Intra-L 23'-88'      134'-194'
                                                      23'''-88''' 134'''-194'''
                                             Inter-H-L 137-214' 137''-214'''
                                             Inter-H-H 229-229'' 232-232''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             300, 300''




                                                                                                                                         89
Recommended INN: List 67                                        WHO Drug Information, Vol. 26, No. 1, 2012


 tefinostatum
 tefinostat                cyclopentyl (2S)-2-[({4-[8-(hydroxyamino)-
                           8-oxooctanamido]phenyl}methyl)amino]-2-phenylacetate

 téfinostat                (2S)-2-[({4-[8-(hydroxyamino)-
                           8-oxooctanamido]phényl}methyl)amino]-2-phénylacétate de
                           cyclopentyle

 tefinostat                (2S)-2-[({4-[8-(hidroxiamino)-8-oxooctanamido]fenil}metil)amino]-
                           2-fenilacetato de ciclopentilo

                           C28H37N3O5



                                           H
                                      O
                                                    N                         O
                                                    H                                           H
                                          O                                                     N
                                                                         N                          OH
                                                                         H
                                                                                            O

 tofacitinibum
 tofacitinib               3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-
                           4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile

 tofacitinib               3-{(3R,4R)-4-méthyl-3-[méthyl(7H-pyrrolo[2,3-d]pyrimidin-
                           4-yl)amino]pipéridin-1-yl}-3-oxopropanenitrile

 tofacitinib               3-{(3R,4R)-4-metil-3-[metil(7H-pirrolo[2,3-d]pirimidin-
                           4-il)amino]piperidin-1-il}-3-oxopropanonitrilo

                           C16H20N6O

                                           H3C
                                  N       N H
                                                            N
                           HN                 N                          CN
                                                  H
                                              CH3               O

 trametinibum
 trametinib                N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-
                           2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-
                           1(2H)-yl}phenyl)acetamide

 tramétinib                N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophényl)amino]-6,8-diméthyl-
                           2,4,7-trioxo-3,4,6,7-tétrahydropyrido[4,3-d]pyrimidin-
                           1(2H)-yl}phényl)acétamide

 trametinib                N-(3-{3-ciclopropil-5-[(2-fluoro-4-iodofenil)amino]-6,8-dimetil-2,4,7-
                           trioxo-3,4,6,7-tetrahidropirido[4,3-d]pirimidin-1(2H)-il}fenil)acetamida

                           C26H23FIN5O4


                                                    O       N        O
                                                                                  F
                                      H                                  H
                           H3 C       N                 N                N

                                  O                                  N
                                                      H3C                CH3          I
                                                                 O


90
WHO Drug Information, Vol. 26, No. 1, 2012                                                Recommended INN: List 67




 upamostatum
 upamostat                                   ethyl 4-{(2S)-3-{3-[(E)- N'-hydroxycarbamimidoyl]phenyl}-
                                             2-[2,3,5-tri(propan-2-yl)benzenesulfonamido]propanoyl}piperazine-
                                             1-carboxylate

 upamostat                                   4-{(2S)-3-{3-[(E)- N'-hydroxycarbamimidoyl]phényl}-
                                             2-[2,3,5-tri(propan-2-yl)benzènesulfonamido]propanoyl}pipérazine-
                                             1-carboxylate d'éthyle

 upamostat                                   4-{(2S)-3-{3-[(E)- N'-hidroxicarbamimidoil]fenil}-2-[2,3,5-tri(propan-
                                             2-il)bencenosulfonamido]propanoil}piperazina-1-carboxilato de etilo

                                             C32H47N5O6S

                                                          H3 C   CH3




                                                   H3 C                 CH3
                                                                                  O
                                                        H3C O S    CH3
                                                                NH
                                             OH              O                N       O   CH3
                                                                   H
                                             N                        N

                                                  NH2               O



 vatelizumabum #
 vatelizumab                                 immunoglobulin G4-kappa, anti-[Homo sapiens ITGA2 (integrin
                                             alpha 2, CD49b, GPIa, subunit of the alpha2beta1 integrin (VLA-2,
                                             collagen receptor))], humanized monoclonal antibody;
                                             gamma4 heavy chain (1-446) [humanized VH (Homo sapiens
                                             IGHV4-59*01 (79.40%) -(IGHD)-IGHJ6*01) [8.7.13] (1-119) -Homo
                                             sapiens IGHG4*01 (120-446)], (133-213')-disulfide with kappa light
                                             chain (1'-213') [humanized V-KAPPA (Homo sapiens IGKV6D-41*01
                                             (77.90%) -IGKJ1*01) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (107'-
                                             213')]; (225-225":228-228")-bisdisulfide dimer

 vatélizumab                                 immunoglobuline G4-kappa, anti-[Homo sapiens ITGA2 (intégrine
                                             alpha 2, CD49b, GPIa, sous-unité de l'intégrine alpha2bêta1 (VLA-2,
                                             récepteur du collagène))], anticorps monoclonal humanisé;
                                             chaîne lourde gamma4 (1-446) [VH humanisé (Homo sapiens
                                             IGHV4-59*01 (79.40%) -(IGHD)-IGHJ6*01) [8.7.13] (1-119) -Homo
                                             sapiens IGHG4*01 (120-446)], (133-213')-disulfure avec la chaîne
                                             légère kappa (1'-213') [V-KAPPA humanisé (Homo sapiens IGKV6D-
                                             41*01 (77.90%) -IGKJ1*01) [5.3.9] (1'-106') -Homo sapiens IGKC*01
                                             (107'-213')]; dimère (225-225":228-228")-bisdisulfure

 vatelizumab                                 inmunoglobulina G4-kappa, anti-[Homo sapiens ITGA2 (integrina
                                             alfa 2, CD49b, GPIa, subunidad de la integrina alfa2beta1 (VLA-2,
                                             receptor del colageno))], anticuerpo monoclonal humanizado;
                                             cadena pesada gamma4 (1-446) [VH humanizada (Homo sapiens
                                             IGHV4-59*01 (79.40%) -(IGHD)-IGHJ6*01) [8.7.13] (1-119) -Homo
                                             sapiens IGHG4*01 (120-446)], (133-213')-disulfuro con la cadena
                                             ligera kappa (1'-213') [V-KAPPA humanizada (Homo sapiens
                                             IGKV6D-41*01 (77.90%) -IGKJ1*01) [5.3.9] (1'-106') -Homo sapiens
                                             IGKC*01 (107'-213')]; dímero (225-225":228-228")-bisdisulfuro




                                                                                                                      91
Recommended INN: List 67                                                        WHO Drug Information, Vol. 26, No. 1, 2012




                                               Heavy chain / Chaîne lourde / Cadena pesada
                                               QVQLQESGPG LVKPSETLSL TCTVSGFSLT                  NYGIHWIRQP       PGKGLEWLGV        50
                                               IWARGFTNYN SALMSRLTIS KDNSKNQVSL                  KLSSVTAADT       AVYYCARAND       100
                                               GVYYAMDYWG QGTLVTVSSA STKGPSVFPL                  APCSRSTSES       TAALGCLVKD       150
                                               YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTKTY       200
                                               TCNVDHKPSN TKVDKRVESK YGPPCPSCPA                  PEFLGGPSVF       LFPPKPKDTL       250
                                               MISRTPEVTC VVVDVSQEDP EVQFNWYVDG                  VEVHNAKTKP       REEQFNSTYR       300
                                               VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS                  IEKTISKAKG       QPREPQVYTL       350
                                               PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW                  ESNGQPENNY       KTTPPVLDSD       400
                                               GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA                  LHNHYTQKSL       SLSLGK           446

                                               Light chain / Chaîne légère / Cadena ligera
                                               DFVMTQSPAF LSVTPGEKVT ITCSAQSSVN                  YIHWYQQKPD       QAPKKLIYDT 50
                                               SKLASGVPSR FSGSGSGTDY TFTISSLEAE                  DAATYYCQQW       TTNPLTFGQG 100
                                               TKVEIKRTVA APSVFIFPPS DEQLKSGTAS                  VVCLLNNFYP       REAKVQWKVD 150
                                               NALQSGNSQE SVTEQDSKDS TYSLSSTLTL                  SKADYEKHKV       YACEVTHQGL 200
                                               SSPVTKSFNR GEC                                                                213

                                               Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                               Intra-H 22-95       146-202        260-320  366-424
                                                        22''-95'' 146''-202'' 260''-320'' 366''-424''
                                               Intra-L 23'-87'      133'-193'
                                                        23'''-87''' 133'''-193'''
                                               Inter-H-L 133-213' 133''-213'''
                                               Inter-H-H 225-225'' 228-228''

                                               N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                               296, 296''




* "INN for pharmaceutical substances: Names for radicals, groups & others" document available at /
document disponible à / documento disponible en :
http://www.who.int/medicines/services/inn/publication/en/index.html

# Electronic structure available on Mednet: http://mednet.who.int/
# Structure électronique disponible sur Mednet: http://mednet.who.int/
# Estructura electrónica disponible en Mednet: http://mednet.who.int/




92
WHO Drug Information, Vol. 26, No. 1, 2012                                                           Recommended INN: List 67




                             AMENDMENTS TO PREVIOUS LISTS
                     MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                         MODIFICACIONES A LAS LISTAS ANTERIORES



Recommended International Non Proprietary Names (Rec. INN): List 6
(Chronicle of the WHO, December 1959, Vol. 13, No. 12)

p. 468         mecamylaminum
               mecamylamine             replace the chemical name by the following

                                        (1RS,2SR,4SR)-N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine



Denominations communes internationales recommandées (DCI Rec.): Liste 6
(Chronique de l'OMS, Vol. 13, No. 12, décembre 1959)

p. 488         mecamylaminum
               mécamylamine             remplacer le nom chimique par le suivant

                                        (1RS,2SR,4SR)-N,2,3,3-tétraméthylbicyclo[2.2.1]heptan-2-amine



Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 6
(Crónica de la OMS, Vol. 13, No. 12, diciembre de 1959)

p. 501         mecamylaminum
               mecamilamina             sustitúyase el nombre químico por el siguiente

                                        (1RS,2SR,4SR)-N,2,3,3-tetrametilbiciclo[2.2.1]heptan-2-amina




Recommended International Non Proprietary Names (Rec. INN): List 31
(WHO Drug Information, Vol. 5, No. 3, 1991)

p. 17      beraprostum
           beraprost                     replace the chemical name and the structure by the following ones

                                         rac-4-{(1R,2R,3aS,8bS)-2-hydroxy-1-[(1E,3S,4RS)-3-hydroxy-4-methyloct-
                                         1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-
                                         5-yl}butanoic acid
                                                                               CO2H
                                                       H
                                                               O
                                             HO
                                              H                           its epimer at C* and their enantiomers
                                                  H        H              son épimère en C* et leurs énantiomères
                                                                          su epímero al C* y sus enantiómeros

                                                  HO
                                                               *
                                                       H
                                                           H       CH3   CH3




                                                                                                                           93
Recommended INN: List 67                                                            WHO Drug Information, Vol. 26, No. 1, 2012




Denominations communes internationales recommandées (DCI Rec.): Liste 31
(Informations pharmaceutiques OMS, Vol. 5, No. 3, 1991)

p. 18     beraprostum
          béraprost                    remplacer le nom chimique et la structure par les suivants

                                       acide rac-4-{(1R,2R,3aS,8bS)-2-hydroxy-1-[(1E,3S,4RS)-3-hydroxy-
                                       4-méthyloct-1-én-6-ynyl]-2,3,3a,8b-tétrahydro-1H-cyclopenta[b][1]benzofuran-
                                       5-yl}butanoïque

                                                                             CO2H
                                                     H
                                                             O
                                       HO
                                           H                            its epimer at C* and their enantiomers
                                               H        H               son épimère en C* et leurs énantiomères
                                                                        su epímero al C* y sus enantiómeros

                                               HO
                                                             *
                                                    H
                                                         H       CH3   CH3



Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 31
(Información farmacéutica OMS, Vol. 5, No. 3, 1991)

p. 18     beraprostum
          beraprost                    sustitúyase el nombre químico y la estructura por los siguientes

                                       ácido rac-4-{(1R,2R,3aS,8bS)-2-hidroxi-1-[(1E,3S,4RS)-3-hidroxi-
                                       4-metiloct-1-en-6-inil]-2,3,3a,8b-tetrahidro-1H-ciclopenta[b][1]benzofuran-
                                        5-il}butanoico

                                                                             CO2H
                                                     H
                                                             O
                                       HO
                                           H                            its epimer at C* and their enantiomers
                                               H        H               son épimère en C* et leurs énantiomères
                                                                        su epímero al C* y sus enantiómeros

                                               HO
                                                             *
                                                    H
                                                         H       CH3   CH3




Recommended International Non Proprietary Names (Rec. INN): List 62
Denominations communes internationales recommandées (DCI Rec.): Liste 62
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 62
(WHO Drug Information, Vol. 23, No. 3, 2009)

p. 250        delete/supprimer/suprimáse            insert/insérer/insertese

              ingenoli mebutatum                    ingenoli mebutas




94
WHO Drug Information, Vol. 26, No. 1, 2012                                                      Recommended INN: List 67




Recommended International Non Proprietary Names (Rec. INN): List 63
Denominations communes internationales recommandées (DCI Rec.): Liste 63
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 63
(WHO Drug Information, Vol. 24, No. 1, 2010)

p. 69          olodaterolum
               olodaterol               replace the chemical name by the following
               olodatérol               remplacer le nom chimique par le suivant
               olodaterol               sustitúyase el nombre químico por el siguiente

                                        6-hydroxy-8-[(1R)-1-hydroxy-2-{[1-(4-methoxyphenyl)-2-methylpropan-
                                        2-yl]amino}ethyl]-2H-1,4-benzoxazin-3(4H)-one

                                        6-hydroxy-8-[(1R)-1-hydroxy-2-{[1-(4-méthoxyphényl)-2-méthylpropan-
                                        2-yl]amino}éthyl]-2H-1,4-benzoxazin-3(4H)-one

                                        6-hidroxi-8-[(1R)-1-hidroxi-2-{[1-(4-metoxifenil)-2-metilpropan-2-il]amino}etil]-
                                        2H-1,4-benzoxazin-3(4H)-ona




Recommended International Non Proprietary Names (Rec. INN): List 64
Denominations communes internationales recommandées (DCI Rec.): Liste 64
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 64
(WHO Drug Information, Vol. 24, No. 3, 2010)

p. 264         condoliasum #
               condoliase                replace the structure by the following
               condoliase                remplacer la structure par la suivante
               condoliasa                sustitúyase la estructura por la siguiente

                                             ATSNPAFDPK   NLMQSEIYHF    AQNNPLADFS     SDKNSILTLS     DKRSIMGNQS     50
                                             LLWKWKGGSS   FTLHKKLIVP    TDKEASKAWG     RSSTPVFSFW     LYNEKPIDGY     100
                                             LTIDFGEKLI   STSEAQAGFK    VKLDFTGWRA     VGVSLNNDLE     NREMTLNATN     150
                                             TSSDGTQDSI   GRSLGAKVDS    IRFKAPSNVS     QGEIYIDRIM     FSVDDARYQW     200
                                             SDYQVKTRLS   EPEIQFHNVK    PQLPVTPENL     AAIDLIRQRL     INEFVGGEKE     250
                                             TNLALEENIS   KLKSDFDALN    IHTLANGGTQ     GRHLITDKQI     IIYQPENLNS     300
                                             QDKQLFDNYV   ILGNYTTLMF    NISRAYVLEK     DPTQKAQLKQ     MYLLMTKHLL     350
                                             DQGFVKGSAL   VTTHHWGYSS    RWWYISTLLM     SDALKEANLQ     TQVYDSLLWY     400
                                             SREFKSSFDM   KVSADSSDLD    YFNTLSRQHL     ALLLLEPDDQ     KRINLVNTFS     450
                                             HYITGALTQV   PPGGKDGLRP    DGTAWRHEGN     YPGYSFPAFK     NASQLIYLLR     500
                                             DTPFSVGESG   WNNLKKAMVS    AWIYSNPEVG     LPLAGRHPFN     SPSLKSVAQG     550
                                             YYWLAMSAKS   SPDKTLASIY    LAISDKTQNE     STAIFGETIT     PASLPQGFYA     600
                                             FNGGAFGIHR   WQDKMVTLKA    YNTNVWSSEI     YNKDNRYGRY     QSHGVAQIVS     650
                                             NGSQLSQGYQ   QEGWDWNRMQ    GATTIHLPLK     DLDSPKPHTL     MQRGERGFSG     700
                                             TSSLEGQYGM   MAFDLIYPAN    LERFDPNFTA     KKSVLAADNH     LIFIGSNINS     750
                                             SDKNKNVETT   LFQHAITPTL    NTLWINGQKI     ENMPYQTTLQ     QGDWLIDSNG     800
                                             NGYLITQAEK   VNVSRQHQVS    AENKNRQPTE     GNFSSAWIDH     STRPKDASYE     850
                                             YMVFLDATPE   KMGEMAQKFR    ENNGLYQVLR     KDKDVHIILD     KLSNVTGYAF     900
                                             YQPASIEDKW   IKKVNKPAIV    MTHRQKDTLI     VSAVTPDLNM     TRQKAATPVT     950
                                             INVTINGKWQ   SADKNSEVKY    QVSGDNTELT     FTSYFGIPQE     IKLSPLP        997




                                                                                                                            95
Recommended INN: List 67                                                WHO Drug Information, Vol. 26, No. 1, 2012




 Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
 The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
 Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
 Substances will be reproduced in proposed INN lists only.
 Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les
 substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales
 applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
 El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias
 farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para
 sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.




96
